Psoriasis
Conditions
Keywords
Xeljanz, tofacitinib, Jak-inhibitor, oral treatment, chronic, severe, moderate, Pruritus, Itch, DLQI, treatment, safety, efficacy, CP-690,550, Plaque Psoriasis, Psoriasis Vulgaris
Brief summary
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
Interventions
DRUGCP-690,550
10 mg oral BID, Continuous treatment for 52 Weeks
0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering at least 10% of body surface area * A Psoriasis Area and Severity Index (PASI) score of 12 or greater * Are considered to be candidates for systemic or light therapy * Have no evidence of active or latent tuberculosis
Exclusion criteria
* Non-plaque or drug-induced forms of psoriasis * Cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB) * Any uncontrolled significant medical condition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 | Week 16 | The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). |
| Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16 | Week 16 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index (DLQI) Total Score | Baseline | The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Baseline, Week 4,16 | The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. |
| Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4 | Week 4 | The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). |
| Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4 | Week 4 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. |
| Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 | Baseline, Week 16 | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. |
| Number of Affected Nails | Baseline, Week 8, 16, 20, 28, 40, 52 | Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number of psoriasis affected nails (presence of psoriatic manifestations on the nail matrix / nail bed) were assessed and reported. 'N' (number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure. |
| Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52 | Week 52 | The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response). |
| Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52 | Week 52 | The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response). |
| Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52 | Week 52 | The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response). |
| Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Baseline up to Week 16 | The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%. |
| Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response | Baseline up to Week 16 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%. |
| Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response | Baseline up to Week 16 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%. |
| Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 2, 4, 8, 12, 16, 20, 28, 40, 52 | The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). |
| Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52 | The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported. |
| Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 2, 4, 8, 12, 16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported. |
| Psoriasis Area and Severity Index (PASI) Score | Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. |
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. |
| Psoriasis Area and Severity Index (PASI) Component Scores | Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 and where higher scores indicate greater severity of psoriatic lesions. |
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 where higher scores indicate greater severity of psoriatic lesions. |
| Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Baseline, Week 2, 4, 8, 12,16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. |
| Total Body Surface Area (BSA) With Psoriasis | Baseline, Week 2, 4, 8,16, 20, 28, 40, 52 | Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected. |
| Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52 | Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected. |
| Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 2, 4, 8,12,16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least a 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported. |
| Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 2, 4, 8,12,16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response is reported. |
| Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 2, 4, 8,12,16, 20, 28, 40, 52 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). |
| Nail Psoriasis Severity Index (NAPSI) Score | Baseline, Week 8, 16, 20, 28, 40, 52 | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.'n' signifies participants evaluable at specified time point for each arm. |
| Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Baseline,Week 8, 16, 20, 28, 40, 52 | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'n' signifies participants evaluable at specified time point for each arm. |
| Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Baseline,Week 8,16, 20, 28, 40, 52 | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'N' (number of participants analyzed) signifies participants with baseline nail psoriasis and who were unique in longitudinal model. |
| Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 8, 16, 20, 28, 40, 52 | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure. |
| Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 8,16, 20, 28, 40, 52 | The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure. |
| Itch Severity Item (ISI) Score | Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52 | ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment. |
| Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Baseline, Week 2, 4, 8,12,16, 20, 28 , 40, 52 | ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends. |
| Dermatology Life Quality Index (DLQI) Score | Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52 | The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52 | The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. Here 'N' (number of participants analyzed) signifies the unique participants in the longitudinal model. |
| 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline, Week 16, 28, 52 | 36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning). |
| Hospital Anxiety and Depression Scale (HADS) Score | Baseline, Week 8, 16, 28, 52 | HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale and 7 items comprising the depression subscale. Each item has response options ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total HADS score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. |
| Work Limitation Questionnaire (WLQ) Index Score | Baseline, Week 8, 16, 28, 52 | WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands Scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]). |
| Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52 | The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe). |
| Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16, 28, 52 | The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from very dissatisfied to very satisfied with the study treatment. |
| Joint Pain Assessment (JPA) Score | Baseline, Week 8,16, 28, 52 | The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to select the number that best describes any joint pain that participant may have experienced over the past 24 hours with response options ranging from 0-no joint pain to 10-worst possible joint pain. |
| Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Baseline, Week 16, 28, 40, 52 | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. |
| Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Baseline,Week 16, 28, 40, 52 | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. |
| Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline, Week 16 | The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist and Rheumatologist. Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure. |
| Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline, Week 16 | The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants (currently employed \[Emp\]) answered (Yes/No \[Y/N\]): Were you absent or on sick leave from work due to psoriasis today?, and participants (unemployed \[UEmp\]) answered (Yes/No): Are you unemployed due to your psoriasis? Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. |
| Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16 | Baseline, Week 16 | Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected. |
| Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline, Week 16 | The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure. |
| Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Baseline, Week 16 | The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure. |
| Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Baseline, Week 16 | The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means ability to work was not affected by psoriasis, and 10 means ability to work was completely affected by psoriasis. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. |
| Family Dermatology Life Quality Index (FDLQI) Score | Baseline, Week 16, 52 | The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure. |
| Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Week 16 | The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. |
| Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16 | Week 16 | The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline. |
Countries
Canada, Colombia, Germany, Hungary, Mexico, Poland, Puerto Rico, Serbia, Taiwan, Ukraine, United States
Participant flow
Pre-assignment details
Outcome measures reporting results up to Week 16 consist of single placebo arm as reporting group while outcome measures reporting results up to Week 52 consist of 2 separate arms (for participants re-randomized at Week 16 to receive CP-690,550 5 milligram \[mg\] or 10 mg).
Participants by arm
| Arm | Count |
|---|---|
| CP-690,550 5mg CP-690,550 5 mg tablet orally twice daily up to Week 52. | 382 |
| CP-690,550 10 mg CP-690,550 10 mg tablet orally twice daily up to Week 52. | 381 |
| Placebo Placebo matched to CP-690,550 tablet orally twice daily up to Week 16. Participants in this group were re-randomized to CP-690,550 5 mg or CP-690,550 10 mg treatment at Week 16. | 196 |
| Total | 959 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Week 0 to 16 | Adverse Event | 11 | 10 | 5 | 0 | 0 |
| Week 0 to 16 | Death | 1 | 0 | 1 | 0 | 0 |
| Week 0 to 16 | Lack of Efficacy | 15 | 2 | 24 | 0 | 0 |
| Week 0 to 16 | Lost to Follow-up | 7 | 8 | 3 | 0 | 0 |
| Week 0 to 16 | Other | 10 | 14 | 4 | 0 | 0 |
| Week 0 to 16 | Randomized, but not treated | 1 | 0 | 0 | 0 | 0 |
| Week 0 to 16 | Withdrawal by Subject | 7 | 6 | 7 | 0 | 0 |
| Week 16 to 52 | Adverse Event | 7 | 7 | 0 | 6 | 5 |
| Week 16 to 52 | Death | 0 | 0 | 0 | 0 | 1 |
| Week 16 to 52 | Lack of Efficacy | 107 | 76 | 0 | 25 | 21 |
| Week 16 to 52 | Lost to Follow-up | 4 | 2 | 0 | 1 | 4 |
| Week 16 to 52 | Other | 10 | 12 | 0 | 2 | 0 |
| Week 16 to 52 | Withdrawal by Subject | 5 | 6 | 0 | 0 | 2 |
Baseline characteristics
| Characteristic | CP-690,550 5mg | CP-690,550 10 mg | Placebo | Total |
|---|---|---|---|---|
| Age, Continuous | 45.9 years STANDARD_DEVIATION 12.9 | 44.3 years STANDARD_DEVIATION 13 | 44.8 years STANDARD_DEVIATION 12.6 | 45.0 years STANDARD_DEVIATION 12.9 |
| Sex: Female, Male Female | 114 Participants | 124 Participants | 73 Participants | 311 Participants |
| Sex: Female, Male Male | 268 Participants | 257 Participants | 123 Participants | 648 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 207 / 382 | 213 / 381 | 43 / 75 | 54 / 77 | 16 / 44 |
| serious Total, serious adverse events | 18 / 382 | 19 / 381 | 4 / 75 | 6 / 77 | 2 / 44 |
Outcome results
Primary
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline.
Time frame: Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16 | 46.01 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16 | 59.63 percentage of participants |
| Placebo | Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 16 | 11.40 percentage of participants |
Comparison: For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.p-value: <0.000195% CI: [5.02, 16.45]Cochran-Mantel-Haenszel
Comparison: For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.p-value: <0.000195% CI: [9, 30.73]Cochran-Mantel-Haenszel
p-value: 0.000295% CI: [6.54, 20.69]Normal Approximation
Primary
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
Time frame: Week 16
Population: Full analysis set (FAS): participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to good clinical practices(GCP) compliance issues. Non-Responder Imputation (NRI) method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 | 46.01 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 | 59.09 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 | 10.88 percentage of participants |
Comparison: For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.p-value: <0.000195% CI: [5.33, 17.68]Cochran-Mantel-Haenszel
Comparison: For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for CP-690,550 10 mg versus (vs) placebo at Week 16; Psoriasis Area and Severity Index 75 (PASI75) response for CP-690,550 10 mg vs placebo at Week 16; PGA response for CP-690,550 5 mg vs placebo at Week 16; PASI75 response for CP-690,550 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparisons were significant.p-value: <0.000195% CI: [8.99, 30.59]Cochran-Mantel-Haenszel
p-value: 0.000395% CI: [5.99, 20.17]Normal approximation
Secondary
36-Item Short-Form Health Survey Version 2, Acute (SF-36)
36-Item Short-Form Health Survey (SF-36) is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects are summarized as physical and mental health summary scores. The score range for the physical and mental health scores is 0-100 (100=highest level of functioning).
Time frame: Baseline, Week 16, 28, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline:Physical Health(n=375,371,74,76) | 46.80 units on a scale | Standard Deviation 9.59 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline: Mental Health(n=375,371,74,76) | 43.24 units on a scale | Standard Deviation 12.04 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Physical Health(n=337,337,74,76) | 51.11 units on a scale | Standard Deviation 8.12 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Mental Health (n=337,337,74,76) | 47.32 units on a scale | Standard Deviation 10.61 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Physical Health(n=300,322,68,72) | 51.85 units on a scale | Standard Deviation 7.81 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Mental Health(n=300,322,68,72) | 47.81 units on a scale | Standard Deviation 10.83 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Physical health(n=194,237,38,42) | 52.38 units on a scale | Standard Deviation 7.25 |
| CP-690,550 5mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Mental Health(n=194,237,38,42) | 49.46 units on a scale | Standard Deviation 10.18 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Mental Health(n=300,322,68,72) | 49.52 units on a scale | Standard Deviation 10.29 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Physical Health(n=300,322,68,72) | 51.79 units on a scale | Standard Deviation 8.7 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline: Mental Health(n=375,371,74,76) | 43.40 units on a scale | Standard Deviation 12.54 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Mental Health(n=194,237,38,42) | 49.99 units on a scale | Standard Deviation 9.45 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Physical health(n=194,237,38,42) | 52.94 units on a scale | Standard Deviation 7.92 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Mental Health (n=337,337,74,76) | 49.07 units on a scale | Standard Deviation 9.72 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Physical Health(n=337,337,74,76) | 51.40 units on a scale | Standard Deviation 8.45 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline:Physical Health(n=375,371,74,76) | 47.25 units on a scale | Standard Deviation 9.05 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Physical health(n=194,237,38,42) | 53.00 units on a scale | Standard Deviation 7.66 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Physical Health(n=337,337,74,76) | 50.03 units on a scale | Standard Deviation 9.56 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Mental Health (n=337,337,74,76) | 45.96 units on a scale | Standard Deviation 11.56 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Physical Health(n=300,322,68,72) | 52.27 units on a scale | Standard Deviation 8.18 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Mental Health(n=300,322,68,72) | 48.06 units on a scale | Standard Deviation 9.17 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Mental Health(n=194,237,38,42) | 46.44 units on a scale | Standard Deviation 9.84 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline:Physical Health(n=375,371,74,76) | 47.39 units on a scale | Standard Deviation 9.42 |
| Placebo | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline: Mental Health(n=375,371,74,76) | 42.98 units on a scale | Standard Deviation 12.43 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Physical Health(n=337,337,74,76) | 48.39 units on a scale | Standard Deviation 10.29 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 16:Mental Health (n=337,337,74,76) | 44.65 units on a scale | Standard Deviation 11.62 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline: Mental Health(n=375,371,74,76) | 43.30 units on a scale | Standard Deviation 12.57 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Baseline:Physical Health(n=375,371,74,76) | 47.90 units on a scale | Standard Deviation 9.57 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Physical Health(n=300,322,68,72) | 50.34 units on a scale | Standard Deviation 9.58 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Mental Health(n=194,237,38,42) | 50.87 units on a scale | Standard Deviation 8.31 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 52:Physical health(n=194,237,38,42) | 51.48 units on a scale | Standard Deviation 8.71 |
| Placebo, Then CP-690,550 10 mg | 36-Item Short-Form Health Survey Version 2, Acute (SF-36) | Week 28:Mental Health(n=300,322,68,72) | 46.67 units on a scale | Standard Deviation 10.86 |
Secondary
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. Here 'N' (number of participants analyzed) signifies the unique participants in the longitudinal model.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -8.20 units on a scale | Standard Error 0.29 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -7.93 units on a scale | Standard Error 0.28 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -8.18 units on a scale | Standard Error 0.32 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -7.03 units on a scale | Standard Error 0.28 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -6.63 units on a scale | Standard Error 0.27 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -5.50 units on a scale | Standard Error 0.24 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -8.23 units on a scale | Standard Error 0.31 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -7.24 units on a scale | Standard Error 0.29 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -3.98 units on a scale | Standard Error 0.22 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -8.95 units on a scale | Standard Error 0.3 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -9.44 units on a scale | Standard Error 0.29 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -9.21 units on a scale | Standard Error 0.27 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -6.89 units on a scale | Standard Error 0.24 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -4.70 units on a scale | Standard Error 0.22 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -8.08 units on a scale | Standard Error 0.27 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -9.43 units on a scale | Standard Error 0.3 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -9.38 units on a scale | Standard Error 0.3 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -8.73 units on a scale | Standard Error 0.28 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -4.01 units on a scale | Standard Error 0.64 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -2.56 units on a scale | Standard Error 0.5 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -3.35 units on a scale | Standard Error 0.53 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -3.97 units on a scale | Standard Error 0.59 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -4.67 units on a scale | Standard Error 0.61 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -8.05 units on a scale | Standard Error 0.6 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -8.80 units on a scale | Standard Error 0.63 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -7.75 units on a scale | Standard Error 0.67 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -7.30 units on a scale | Standard Error 0.7 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -8.07 units on a scale | Standard Error 0.62 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -2.21 units on a scale | Standard Error 0.61 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -2.78 units on a scale | Standard Error 0.58 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -8.01 units on a scale | Standard Error 0.67 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -8.31 units on a scale | Standard Error 0.65 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -3.00 units on a scale | Standard Error 0.53 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -6.49 units on a scale | Standard Error 0.59 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -2.44 units on a scale | Standard Error 0.64 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -2.95 units on a scale | Standard Error 0.49 |
Secondary
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16
The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline, Week 4,16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Change at Week 4 | -5.55 units on a scale | Standard Error 0.24 |
| CP-690,550 5mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Change at Week 16 | -7.28 units on a scale | Standard Error 0.3 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Change at Week 4 | -6.88 units on a scale | Standard Error 0.25 |
| CP-690,550 10 mg | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Change at Week 16 | -8.92 units on a scale | Standard Error 0.31 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Change at Week 4 | -2.57 units on a scale | Standard Error 0.35 |
| Placebo | Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 4 and 16 | Change at Week 16 | -2.82 units on a scale | Standard Error 0.44 |
Comparison: Week4: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [-3.8, -2.14]Mixed Models Analysis
Comparison: Week 4: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [-5.13, -3.47]Mixed Models Analysis
Comparison: Week 4: LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.p-value: 0.000195% CI: [-2.01, -0.65]Mixed Models Analysis
Comparison: Week 16: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [-5.51, -3.42]Mixed Models Analysis
Comparison: Week 16: For key secondary endpoint, family-wise step-down procedure was used to control Type I error.Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [-7.14, -5.05]Mixed Models Analysis
Comparison: Week 16: LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.p-value: 0.000295% CI: [-2.48, -0.79]Mixed Models Analysis
Secondary
Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends.
Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28 , 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'N' (number of participants analyzed) signifies the unique participants in the longitudinal model.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -3.35 units on a scale | Standard Error 0.13 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -3.37 units on a scale | Standard Error 0.13 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -3.03 units on a scale | Standard Error 0.16 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -2.99 units on a scale | Standard Error 0.13 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -2.84 units on a scale | Standard Error 0.13 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -2.39 units on a scale | Standard Error 0.12 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -3.23 units on a scale | Standard Error 0.15 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -3.15 units on a scale | Standard Error 0.13 |
| CP-690,550 5mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -1.72 units on a scale | Standard Error 0.11 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -3.78 units on a scale | Standard Error 0.13 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -3.88 units on a scale | Standard Error 0.13 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -3.97 units on a scale | Standard Error 0.13 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -3.05 units on a scale | Standard Error 0.12 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -2.05 units on a scale | Standard Error 0.11 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -3.63 units on a scale | Standard Error 0.13 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -3.62 units on a scale | Standard Error 0.15 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -3.59 units on a scale | Standard Error 0.15 |
| CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -3.68 units on a scale | Standard Error 0.13 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -0.58 units on a scale | Standard Error 0.29 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -0.44 units on a scale | Standard Error 0.24 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -0.78 units on a scale | Standard Error 0.26 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -0.64 units on a scale | Standard Error 0.27 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -0.95 units on a scale | Standard Error 0.28 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -3.13 units on a scale | Standard Error 0.27 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -3.32 units on a scale | Standard Error 0.28 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -2.97 units on a scale | Standard Error 0.33 |
| Placebo | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -2.71 units on a scale | Standard Error 0.36 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -3.79 units on a scale | Standard Error 0.29 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -0.21 units on a scale | Standard Error 0.29 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -0.31 units on a scale | Standard Error 0.28 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -3.14 units on a scale | Standard Error 0.36 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -3.69 units on a scale | Standard Error 0.32 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -0.43 units on a scale | Standard Error 0.26 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -2.87 units on a scale | Standard Error 0.28 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -0.00 units on a scale | Standard Error 0.3 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Itch Severity Item (ISI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -0.63 units on a scale | Standard Error 0.25 |
Secondary
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'n' signifies participants evaluable at specified time point for each arm.
Time frame: Baseline,Week 8, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP non-compliance. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 16(n=218,205,43,55) | -8.74 units on a scale | Standard Deviation 14.02 |
| CP-690,550 5mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 40(n=118,148,26,39) | -16.45 units on a scale | Standard Deviation 14.8 |
| CP-690,550 5mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 8(n=226,214,43,55) | -4.33 units on a scale | Standard Deviation 11.3 |
| CP-690,550 5mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 28(n=193,197,40,53) | -13.86 units on a scale | Standard Deviation 14.96 |
| CP-690,550 5mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 20(n=208,206,43,55) | -10.61 units on a scale | Standard Deviation 15.48 |
| CP-690,550 5mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 52(n=108,137,21,30) | -17.08 units on a scale | Standard Deviation 15.36 |
| CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 20(n=208,206,43,55) | -11.50 units on a scale | Standard Deviation 14.74 |
| CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 28(n=193,197,40,53) | -14.30 units on a scale | Standard Deviation 14.75 |
| CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 52(n=108,137,21,30) | -18.13 units on a scale | Standard Deviation 15.27 |
| CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 16(n=218,205,43,55) | -9.36 units on a scale | Standard Deviation 13.6 |
| CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 40(n=118,148,26,39) | -18.11 units on a scale | Standard Deviation 15.84 |
| CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 8(n=226,214,43,55) | -4.21 units on a scale | Standard Deviation 10.8 |
| Placebo | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 20(n=208,206,43,55) | -3.95 units on a scale | Standard Deviation 14.31 |
| Placebo | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 8(n=226,214,43,55) | -3.53 units on a scale | Standard Deviation 10.35 |
| Placebo | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 16(n=218,205,43,55) | -2.86 units on a scale | Standard Deviation 12.72 |
| Placebo | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 52(n=108,137,21,30) | -23.29 units on a scale | Standard Deviation 19.97 |
| Placebo | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 28(n=193,197,40,53) | -9.45 units on a scale | Standard Deviation 17.63 |
| Placebo | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 40(n=118,148,26,39) | -21.50 units on a scale | Standard Deviation 17.28 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 20(n=208,206,43,55) | -2.49 units on a scale | Standard Deviation 10.63 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 16(n=218,205,43,55) | -1.09 units on a scale | Standard Deviation 11.07 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 52(n=108,137,21,30) | -19.17 units on a scale | Standard Deviation 13.88 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 40(n=118,148,26,39) | -15.33 units on a scale | Standard Deviation 12.6 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 8(n=226,214,43,55) | -1.04 units on a scale | Standard Deviation 8.54 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Change at Week 28(n=193,197,40,53) | -8.91 units on a scale | Standard Deviation 12.9 |
Secondary
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 where higher scores indicate greater severity of psoriatic lesions.
Time frame: Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | -1.69 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Trunk)(n=369,367,73,76) | -0.36 units on a scale | Standard Deviation 0.64 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Upper limbs)(n=194,239,38,42) | -2.00 units on a scale | Standard Deviation 1.09 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | -0.84 units on a scale | Standard Deviation 0.85 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | -1.09 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Upper limbs)(n=213,263,46,55) | -2.04 units on a scale | Standard Deviation 1.06 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Upper limbs)(n=305,327,69,72) | -1.69 units on a scale | Standard Deviation 1.13 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | -1.25 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Trunk)(n=340,345,74,76) | -1.61 units on a scale | Standard Deviation 1.28 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Upper limbs)(n=327,338,74,76) | -1.64 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Upper limbs)(n=340,345,74,76) | -1.51 units on a scale | Standard Deviation 1.19 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | -1.46 units on a scale | Standard Deviation 1.12 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Trunk)(n=347,348,74,76) | -1.48 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Upper limbs)(n=347,348,74,76) | -1.42 units on a scale | Standard Deviation 1.09 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Upper limbs)(n=354,356,74,76) | -1.18 units on a scale | Standard Deviation 1.01 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | -1.68 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | -1.64 units on a scale | Standard Deviation 1.06 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Upper limbs)(n=363,366,74,75) | -0.87 units on a scale | Standard Deviation 0.85 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Upper limbs)(n=369,367,73,76) | -0.42 units on a scale | Standard Deviation 0.65 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | -1.84 units on a scale | Standard Deviation 1.18 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | -2.31 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Head\Neck)(n=194,239,38,42) | -1.64 units on a scale | Standard Deviation 1.12 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Head\Neck)(n=213,263,46,55) | -1.67 units on a scale | Standard Deviation 1.12 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | -1.98 units on a scale | Standard Deviation 1.18 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Trunk)(n=354,356,74,76) | -1.27 units on a scale | Standard Deviation 1.15 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Head\Neck)(n=305,327,69,72) | -1.41 units on a scale | Standard Deviation 1.14 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Head\Neck)(n=327,338,74,76) | -1.33 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | -2.38 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Trunk)(n=363,366,74,75) | -0.85 units on a scale | Standard Deviation 0.97 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Head\Neck)(n=340,345,74,76) | -1.20 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Head\Neck)(n=347,348,74,76) | -1.18 units on a scale | Standard Deviation 1.21 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | -2.32 units on a scale | Standard Deviation 1.12 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | -0.48 units on a scale | Standard Deviation 0.71 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Head\Neck)(n=354,356,74,76) | -1.05 units on a scale | Standard Deviation 1.12 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Head\Neck)(n=363,366,74,75) | -0.81 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Head\Neck)(n=369,367,73,76) | -0.36 units on a scale | Standard Deviation 0.72 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | -1.84 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Trunk)(n=369,367,73,76) | -0.50 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | -1.92 units on a scale | Standard Deviation 1.21 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | -0.89 units on a scale | Standard Deviation 0.86 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | -1.64 units on a scale | Standard Deviation 1.29 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | -1.93 units on a scale | Standard Deviation 1.25 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | -1.69 units on a scale | Standard Deviation 1.22 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | -1.18 units on a scale | Standard Deviation 0.98 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | -1.25 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | -1.63 units on a scale | Standard Deviation 1.19 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | -1.47 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | -1.40 units on a scale | Standard Deviation 1.08 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | -0.85 units on a scale | Standard Deviation 0.97 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | -1.39 units on a scale | Standard Deviation 1.19 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | -1.23 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | -1.53 units on a scale | Standard Deviation 1.16 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | -1.52 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | -0.92 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | -0.51 units on a scale | Standard Deviation 0.79 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | -1.66 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | -1.34 units on a scale | Standard Deviation 1.15 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | -1.71 units on a scale | Standard Deviation 1.11 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | -1.70 units on a scale | Standard Deviation 1.21 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | -1.72 units on a scale | Standard Deviation 1.13 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | -1.27 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | -1.54 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | -1.49 units on a scale | Standard Deviation 1.21 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | -2.05 units on a scale | Standard Deviation 1.04 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | -0.48 units on a scale | Standard Deviation 0.76 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | -1.34 units on a scale | Standard Deviation 1.29 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | -1.37 units on a scale | Standard Deviation 1.25 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | -1.99 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | -0.88 units on a scale | Standard Deviation 0.97 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | -1.20 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | -0.92 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Trunk)(n=369,367,73,76) | -0.47 units on a scale | Standard Deviation 0.69 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | -0.49 units on a scale | Standard Deviation 0.74 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | -0.53 units on a scale | Standard Deviation 0.86 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Lower limbs)(n=194,239,38,42) | -2.30 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Trunk)(n=363,366,74,75) | -0.86 units on a scale | Standard Deviation 0.9 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | -1.39 units on a scale | Standard Deviation 1.16 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Lower limbs)(n=213,263,46,55) | -2.31 units on a scale | Standard Deviation 1.1 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Lower limbs)(n=305,327,69,72) | -1.87 units on a scale | Standard Deviation 1.22 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Trunk)(n=354,356,74,76) | -1.18 units on a scale | Standard Deviation 1.09 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | -2.31 units on a scale | Standard Deviation 1.21 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Lower limbs)(n=327,338,74,76) | -1.76 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Lower limbs)(n=340,345,74,76) | -1.63 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Trunk)(n=347,348,74,76) | -1.41 units on a scale | Standard Deviation 1.19 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Trunk)(n=194,239,38,42) | -2.13 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Lower limbs)(n=347,348,74,76) | -1.46 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Lower limbs)(n=354,356,74,76) | -1.23 units on a scale | Standard Deviation 1.09 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Trunk)(n=340,345,74,76) | -1.58 units on a scale | Standard Deviation 1.25 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Trunk)(n=213,263,46,55) | -2.15 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Lower limbs)(n=363,366,74,75) | -0.80 units on a scale | Standard Deviation 0.88 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Lower limbs)(n=369,367,73,76) | -0.35 units on a scale | Standard Deviation 0.65 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Trunk)(n=327,338,74,76) | -1.80 units on a scale | Standard Deviation 1.25 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | -1.46 units on a scale | Standard Deviation 1.1 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Trunk)(n=194,239,38,42) | -2.17 units on a scale | Standard Deviation 1.15 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Trunk)(n=213,263,46,55) | -2.20 units on a scale | Standard Deviation 1.09 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Trunk)(n=305,327,69,72) | -1.94 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | -1.96 units on a scale | Standard Deviation 1.27 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Trunk)(n=305,327,69,72) | -1.83 units on a scale | Standard Deviation 1.21 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Trunk)(n=327,338,74,76) | -1.72 units on a scale | Standard Deviation 1.28 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Trunk)(n=213,263,46,55) | -2.26 units on a scale | Standard Deviation 1.04 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Trunk)(n=305,327,69,72) | -1.92 units on a scale | Standard Deviation 1.18 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Trunk)(n=340,345,74,76) | -1.52 units on a scale | Standard Deviation 1.31 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Trunk)(n=347,348,74,76) | -1.40 units on a scale | Standard Deviation 1.2 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Trunk)(n=194,239,38,42) | -2.19 units on a scale | Standard Deviation 1.13 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Trunk)(n=327,338,74,76) | -1.81 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Trunk)(n=354,356,74,76) | -1.15 units on a scale | Standard Deviation 1.11 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Trunk)(n=363,366,74,75) | -0.79 units on a scale | Standard Deviation 0.89 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | -0.40 units on a scale | Standard Deviation 0.66 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | -0.56 units on a scale | Standard Deviation 0.77 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | -1.01 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | -1.35 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | -1.54 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | -1.57 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | -1.62 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | -1.64 units on a scale | Standard Deviation 1.18 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | -1.79 units on a scale | Standard Deviation 1.14 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | -1.82 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | -0.63 units on a scale | Standard Deviation 0.68 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | -1.08 units on a scale | Standard Deviation 0.9 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | -1.51 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | -1.71 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | -1.81 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | -1.91 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | -1.92 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | -2.15 units on a scale | Standard Deviation 1 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | -2.15 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Trunk)(n=369,367,73,76) | -0.59 units on a scale | Standard Deviation 0.7 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Trunk)(n=363,366,74,75) | -1.04 units on a scale | Standard Deviation 0.9 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Trunk)(n=354,356,74,76) | -1.56 units on a scale | Standard Deviation 1.07 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Trunk)(n=347,348,74,76) | -1.82 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Trunk)(n=340,345,74,76) | -1.99 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Trunk)(n=327,338,74,76) | -2.12 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Trunk)(n=305,327,69,72) | -2.12 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Trunk)(n=213,263,46,55) | -2.31 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Trunk)(n=194,239,38,42) | -2.36 units on a scale | Standard Deviation 1.03 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | -0.55 units on a scale | Standard Deviation 0.68 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | -1.07 units on a scale | Standard Deviation 0.87 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | -1.57 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | -1.85 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | -2.00 units on a scale | Standard Deviation 1.18 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | -2.15 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | -2.21 units on a scale | Standard Deviation 1.22 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | -2.46 units on a scale | Standard Deviation 1.08 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | -2.44 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Head\Neck)(n=369,367,73,76) | -0.51 units on a scale | Standard Deviation 0.76 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Head\Neck)(n=363,366,74,75) | -0.97 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Head\Neck)(n=354,356,74,76) | -1.27 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Head\Neck)(n=347,348,74,76) | -1.42 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Head\Neck)(n=340,345,74,76) | -1.45 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Head\Neck)(n=327,338,74,76) | -1.54 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Head\Neck)(n=305,327,69,72) | -1.55 units on a scale | Standard Deviation 1.14 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Head\Neck)(n=213,263,46,55) | -1.66 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Head\Neck)(n=194,239,38,42) | -1.72 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Upper limbs)(n=369,367,73,76) | -0.54 units on a scale | Standard Deviation 0.7 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Upper limbs)(n=363,366,74,75) | -1.07 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Upper limbs)(n=354,356,74,76) | -1.46 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Upper limbs)(n=347,348,74,76) | -1.61 units on a scale | Standard Deviation 1.14 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Upper limbs)(n=340,345,74,76) | -1.68 units on a scale | Standard Deviation 1.2 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Upper limbs)(n=327,338,74,76) | -1.79 units on a scale | Standard Deviation 1.2 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Upper limbs)(n=305,327,69,72) | -1.79 units on a scale | Standard Deviation 1.23 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Upper limbs)(n=213,263,46,55) | -2.05 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Upper limbs)(n=194,239,38,42) | -2.10 units on a scale | Standard Deviation 1.02 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Trunk)(n=369,367,73,76) | -0.50 units on a scale | Standard Deviation 0.7 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Trunk)(n=363,366,74,75) | -1.01 units on a scale | Standard Deviation 0.94 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Trunk)(n=354,356,74,76) | -1.54 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Trunk)(n=347,348,74,76) | -1.79 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Trunk)(n=340,345,74,76) | -1.94 units on a scale | Standard Deviation 1.19 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Trunk)(n=327,338,74,76) | -2.04 units on a scale | Standard Deviation 1.14 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Trunk)(n=305,327,69,72) | -2.07 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Trunk)(n=213,263,46,55) | -2.25 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Trunk)(n=194,239,38,42) | -2.32 units on a scale | Standard Deviation 1.03 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Lower limbs)(n=369,367,73,76) | -0.51 units on a scale | Standard Deviation 0.7 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Lower limbs)(n=363,366,74,75) | -1.06 units on a scale | Standard Deviation 0.96 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Lower limbs)(n=354,356,74,76) | -1.59 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Lower limbs)(n=347,348,74,76) | -1.86 units on a scale | Standard Deviation 1.2 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Lower limbs)(n=340,345,74,76) | -1.97 units on a scale | Standard Deviation 1.25 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Lower limbs)(n=327,338,74,76) | -2.12 units on a scale | Standard Deviation 1.21 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Lower limbs)(n=305,327,69,72) | -2.19 units on a scale | Standard Deviation 1.27 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Lower limbs)(n=213,263,46,55) | -2.43 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Lower limbs)(n=194,239,38,42) | -2.40 units on a scale | Standard Deviation 1.08 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | -0.65 units on a scale | Standard Deviation 0.83 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | -1.13 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | -1.44 units on a scale | Standard Deviation 1.18 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | -1.60 units on a scale | Standard Deviation 1.22 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | -1.66 units on a scale | Standard Deviation 1.22 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | -1.69 units on a scale | Standard Deviation 1.23 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | -1.70 units on a scale | Standard Deviation 1.2 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | -1.83 units on a scale | Standard Deviation 1.2 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | -1.86 units on a scale | Standard Deviation 1.19 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | -0.60 units on a scale | Standard Deviation 0.73 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | -1.12 units on a scale | Standard Deviation 0.98 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | -1.47 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | -1.65 units on a scale | Standard Deviation 1.18 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | -1.73 units on a scale | Standard Deviation 1.24 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | -1.76 units on a scale | Standard Deviation 1.23 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | -1.82 units on a scale | Standard Deviation 1.3 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | -2.07 units on a scale | Standard Deviation 1.18 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | -2.13 units on a scale | Standard Deviation 1.14 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Trunk)(n=369,367,73,76) | -0.57 units on a scale | Standard Deviation 0.78 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Trunk)(n=363,366,74,75) | -1.08 units on a scale | Standard Deviation 0.99 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Trunk)(n=354,356,74,76) | -1.59 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Trunk)(n=347,348,74,76) | -1.81 units on a scale | Standard Deviation 1.18 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Trunk)(n=340,345,74,76) | -1.95 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Trunk)(n=327,338,74,76) | -2.04 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Trunk)(n=305,327,69,72) | -2.07 units on a scale | Standard Deviation 1.19 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Trunk)(n=213,263,46,55) | -2.25 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Trunk)(n=194,239,38,42) | -2.30 units on a scale | Standard Deviation 1.03 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | -0.56 units on a scale | Standard Deviation 0.75 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | -1.10 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | -1.69 units on a scale | Standard Deviation 1.19 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | -1.97 units on a scale | Standard Deviation 1.2 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | -2.05 units on a scale | Standard Deviation 1.28 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | -2.16 units on a scale | Standard Deviation 1.29 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | -2.22 units on a scale | Standard Deviation 1.33 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | -2.48 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | -2.49 units on a scale | Standard Deviation 1.12 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Head\Neck)(n=340,345,74,76) | -0.58 units on a scale | Standard Deviation 1.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Trunk)(n=369,367,73,76) | -0.16 units on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Trunk)(n=363,366,74,75) | -0.42 units on a scale | Standard Deviation 0.91 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Trunk)(n=194,239,38,42) | -2.29 units on a scale | Standard Deviation 1.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Trunk)(n=354,356,74,76) | -0.59 units on a scale | Standard Deviation 1.06 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Trunk)(n=327,338,74,76) | -1.46 units on a scale | Standard Deviation 1.21 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Trunk)(n=347,348,74,76) | -0.58 units on a scale | Standard Deviation 1.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Trunk)(n=213,263,46,55) | -2.28 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Trunk)(n=340,345,74,76) | -0.68 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | -1.42 units on a scale | Standard Deviation 1.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Trunk)(n=327,338,74,76) | -1.28 units on a scale | Standard Deviation 1.21 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Trunk)(n=305,327,69,72) | -1.88 units on a scale | Standard Deviation 1.28 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | -2.29 units on a scale | Standard Deviation 1.27 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Trunk)(n=305,327,69,72) | -1.74 units on a scale | Standard Deviation 1.29 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Trunk)(n=305,327,69,72) | -1.80 units on a scale | Standard Deviation 1.37 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Trunk)(n=213,263,46,55) | -2.22 units on a scale | Standard Deviation 1.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Trunk)(n=327,338,74,76) | -1.36 units on a scale | Standard Deviation 1.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Trunk)(n=194,239,38,42) | -2.18 units on a scale | Standard Deviation 1.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Lower limbs)(n=369,367,73,76) | -0.14 units on a scale | Standard Deviation 0.54 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Trunk)(n=340,345,74,76) | -0.88 units on a scale | Standard Deviation 1.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | -1.81 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Lower limbs)(n=363,366,74,75) | -0.31 units on a scale | Standard Deviation 0.76 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Trunk)(n=213,263,46,55) | -2.33 units on a scale | Standard Deviation 1.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Lower limbs)(n=354,356,74,76) | -0.45 units on a scale | Standard Deviation 0.98 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Trunk)(n=347,348,74,76) | -0.72 units on a scale | Standard Deviation 1.08 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Lower limbs)(n=347,348,74,76) | -0.50 units on a scale | Standard Deviation 1.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | -1.03 units on a scale | Standard Deviation 1.06 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Lower limbs)(n=340,345,74,76) | -0.55 units on a scale | Standard Deviation 1.21 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Trunk)(n=354,356,74,76) | -0.69 units on a scale | Standard Deviation 1.05 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Lower limbs)(n=327,338,74,76) | -1.19 units on a scale | Standard Deviation 1.24 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Trunk)(n=194,239,38,42) | -2.18 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Lower limbs)(n=305,327,69,72) | -1.58 units on a scale | Standard Deviation 1.39 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Trunk)(n=363,366,74,75) | -0.46 units on a scale | Standard Deviation 0.91 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Lower limbs)(n=213,263,46,55) | -2.15 units on a scale | Standard Deviation 1.23 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Lower limbs)(n=194,239,38,42) | -2.26 units on a scale | Standard Deviation 1.25 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Trunk)(n=369,367,73,76) | -0.14 units on a scale | Standard Deviation 0.58 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | -0.26 units on a scale | Standard Deviation 0.7 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | -0.14 units on a scale | Standard Deviation 0.61 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | -0.32 units on a scale | Standard Deviation 0.66 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | -0.47 units on a scale | Standard Deviation 0.95 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | -1.92 units on a scale | Standard Deviation 1.08 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | -0.65 units on a scale | Standard Deviation 1.05 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | -0.46 units on a scale | Standard Deviation 1.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | -0.70 units on a scale | Standard Deviation 1.07 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | -1.96 units on a scale | Standard Deviation 1.07 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | -0.73 units on a scale | Standard Deviation 1.24 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | -0.46 units on a scale | Standard Deviation 0.83 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | -1.36 units on a scale | Standard Deviation 1.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | -1.57 units on a scale | Standard Deviation 1.23 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | -1.62 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | -1.93 units on a scale | Standard Deviation 1.32 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | -1.23 units on a scale | Standard Deviation 1.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | -2.22 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | -2.00 units on a scale | Standard Deviation 1.21 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | -0.69 units on a scale | Standard Deviation 0.99 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | -0.22 units on a scale | Standard Deviation 0.58 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | -0.73 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | -0.47 units on a scale | Standard Deviation 0.85 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | -0.50 units on a scale | Standard Deviation 1.01 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | -0.61 units on a scale | Standard Deviation 0.9 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | -0.65 units on a scale | Standard Deviation 1.05 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | -0.74 units on a scale | Standard Deviation 1.02 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | -0.73 units on a scale | Standard Deviation 1.08 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | -0.74 units on a scale | Standard Deviation 1.23 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | -0.54 units on a scale | Standard Deviation 0.88 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | -1.38 units on a scale | Standard Deviation 1.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | -1.57 units on a scale | Standard Deviation 1.25 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | -0.30 units on a scale | Standard Deviation 0.7 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | -2.02 units on a scale | Standard Deviation 1.24 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | -0.86 units on a scale | Standard Deviation 1.2 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | -1.95 units on a scale | Standard Deviation 1.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | -0.12 units on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Head\Neck)(n=369,367,73,76) | -0.12 units on a scale | Standard Deviation 0.55 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Trunk)(n=369,367,73,76) | -0.33 units on a scale | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Head\Neck)(n=363,366,74,75) | -0.38 units on a scale | Standard Deviation 0.81 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | -2.39 units on a scale | Standard Deviation 1.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Head\Neck)(n=354,356,74,76) | -0.62 units on a scale | Standard Deviation 1.02 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Head\Neck)(n=347,348,74,76) | -0.64 units on a scale | Standard Deviation 1.07 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | -2.17 units on a scale | Standard Deviation 1.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | -0.51 units on a scale | Standard Deviation 0.95 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Trunk)(n=363,366,74,75) | -0.54 units on a scale | Standard Deviation 0.97 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Head\Neck)(n=327,338,74,76) | -1.14 units on a scale | Standard Deviation 1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | -1.80 units on a scale | Standard Deviation 1.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Head\Neck)(n=305,327,69,72) | -1.41 units on a scale | Standard Deviation 1.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | -1.66 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Head\Neck)(n=213,263,46,55) | -1.78 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | -1.34 units on a scale | Standard Deviation 1.2 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | -0.05 units on a scale | Standard Deviation 0.5 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Head\Neck)(n=194,239,38,42) | -1.74 units on a scale | Standard Deviation 1.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Trunk)(n=354,356,74,76) | -0.74 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Upper limbs)(n=369,367,73,76) | -0.12 units on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | -0.74 units on a scale | Standard Deviation 1.07 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Upper limbs)(n=363,366,74,75) | -0.26 units on a scale | Standard Deviation 0.74 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Upper limbs)(n=354,356,74,76) | -0.53 units on a scale | Standard Deviation 0.89 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | -0.66 units on a scale | Standard Deviation 0.95 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | -1.59 units on a scale | Standard Deviation 1.12 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Upper limbs)(n=347,348,74,76) | -0.57 units on a scale | Standard Deviation 0.98 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Trunk)(n=347,348,74,76) | -0.80 units on a scale | Standard Deviation 1.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Upper limbs)(n=340,345,74,76) | -0.59 units on a scale | Standard Deviation 1.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | -0.61 units on a scale | Standard Deviation 0.89 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Upper limbs)(n=327,338,74,76) | -1.23 units on a scale | Standard Deviation 1.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | -1.67 units on a scale | Standard Deviation 1.21 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Upper limbs)(n=305,327,69,72) | -1.55 units on a scale | Standard Deviation 1.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | -0.42 units on a scale | Standard Deviation 0.72 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Upper limbs)(n=213,263,46,55) | -1.91 units on a scale | Standard Deviation 1.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Trunk)(n=340,345,74,76) | -0.93 units on a scale | Standard Deviation 1.24 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Upper limbs)(n=194,239,38,42) | -1.87 units on a scale | Standard Deviation 1.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | -0.10 units on a scale | Standard Deviation 0.48 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Head\Neck)(n=340,345,74,76) | -0.47 units on a scale | Standard Deviation 0.97 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | -2.19 units on a scale | Standard Deviation 1.15 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Trunk)(n=369,367,73,76) | -0.26 units on a scale | Standard Deviation 0.6 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Trunk)(n=194,239,38,42) | -2.48 units on a scale | Standard Deviation 1.06 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | -1.56 units on a scale | Standard Deviation 1.1 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | -0.43 units on a scale | Standard Deviation 0.62 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Trunk)(n=363,366,74,75) | -0.28 units on a scale | Standard Deviation 0.81 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | -1.78 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | -0.25 units on a scale | Standard Deviation 0.7 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | -0.62 units on a scale | Standard Deviation 0.92 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Trunk)(n=354,356,74,76) | -0.38 units on a scale | Standard Deviation 0.92 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Trunk)(n=213,263,46,55) | -2.45 units on a scale | Standard Deviation 1.12 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | -1.53 units on a scale | Standard Deviation 1.23 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | -0.52 units on a scale | Standard Deviation 0.81 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Trunk)(n=347,348,74,76) | -0.43 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | -0.57 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Trunk)(n=327,338,74,76) | -1.39 units on a scale | Standard Deviation 1.16 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Head\Neck)(n=327,338,74,76) | -1.11 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Trunk)(n=340,345,74,76) | -0.54 units on a scale | Standard Deviation 1.1 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Trunk)(n=305,327,69,72) | -1.94 units on a scale | Standard Deviation 1.32 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Upper limbs)(n=354,356,74,76) | -0.53 units on a scale | Standard Deviation 0.66 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | -0.59 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Trunk)(n=327,338,74,76) | -1.38 units on a scale | Standard Deviation 1.13 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Trunk)(n=363,366,74,75) | -0.43 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | -2.38 units on a scale | Standard Deviation 1.24 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Upper limbs)(n=327,338,74,76) | -1.49 units on a scale | Standard Deviation 1.14 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Trunk)(n=305,327,69,72) | -1.94 units on a scale | Standard Deviation 1.28 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Trunk)(n=327,338,74,76) | -1.21 units on a scale | Standard Deviation 1.16 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | -0.70 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | -0.38 units on a scale | Standard Deviation 0.8 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Trunk)(n=213,263,46,55) | -2.29 units on a scale | Standard Deviation 1.12 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Head\Neck)(n=305,327,69,72) | -1.44 units on a scale | Standard Deviation 1.12 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Trunk)(n=305,327,69,72) | -1.88 units on a scale | Standard Deviation 1.29 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | -1.39 units on a scale | Standard Deviation 1.06 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Trunk)(n=194,239,38,42) | -2.24 units on a scale | Standard Deviation 1.19 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Trunk)(n=340,345,74,76) | -0.50 units on a scale | Standard Deviation 1.09 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | -1.18 units on a scale | Standard Deviation 1.14 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | -0.68 units on a scale | Standard Deviation 1 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Lower limbs)(n=369,367,73,76) | -0.26 units on a scale | Standard Deviation 0.53 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | -0.36 units on a scale | Standard Deviation 0.8 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | -0.72 units on a scale | Standard Deviation 1.11 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Upper limbs)(n=194,239,38,42) | -2.29 units on a scale | Standard Deviation 1.13 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Lower limbs)(n=363,366,74,75) | -0.40 units on a scale | Standard Deviation 0.75 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Trunk)(n=347,348,74,76) | -0.42 units on a scale | Standard Deviation 1.02 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | -1.42 units on a scale | Standard Deviation 1 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | -0.32 units on a scale | Standard Deviation 0.7 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Lower limbs)(n=354,356,74,76) | -0.41 units on a scale | Standard Deviation 0.73 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | -0.50 units on a scale | Standard Deviation 0.82 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Trunk)(n=213,263,46,55) | -2.18 units on a scale | Standard Deviation 1.2 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Head\Neck)(n=213,263,46,55) | -1.73 units on a scale | Standard Deviation 1.03 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Lower limbs)(n=347,348,74,76) | -0.50 units on a scale | Standard Deviation 0.95 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Trunk)(n=354,356,74,76) | -0.34 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | -1.71 units on a scale | Standard Deviation 1.24 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Upper limbs)(n=347,348,74,76) | -0.64 units on a scale | Standard Deviation 0.86 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Lower limbs)(n=340,345,74,76) | -0.59 units on a scale | Standard Deviation 0.98 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | -0.22 units on a scale | Standard Deviation 0.53 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | -2.15 units on a scale | Standard Deviation 1.26 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | -0.45 units on a scale | Standard Deviation 0.87 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Induration(Lower limbs)(n=327,338,74,76) | -1.46 units on a scale | Standard Deviation 1 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Erythema(Trunk)(n=363,366,74,75) | -0.31 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | -1.95 units on a scale | Standard Deviation 1.24 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | -0.29 units on a scale | Standard Deviation 0.63 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Lower limbs)(n=305,327,69,72) | -2.07 units on a scale | Standard Deviation 1.2 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Upper limbs)(n=213,263,46,55) | -2.20 units on a scale | Standard Deviation 1.11 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Trunk)(n=194,239,38,42) | -2.14 units on a scale | Standard Deviation 1.18 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Head\Neck)(n=194,239,38,42) | -1.83 units on a scale | Standard Deviation 1.08 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Induration(Lower limbs)(n=213,263,46,55) | -2.40 units on a scale | Standard Deviation 0.97 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Trunk)(n=369,367,73,76) | -0.25 units on a scale | Standard Deviation 0.66 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | -0.54 units on a scale | Standard Deviation 0.9 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | -1.95 units on a scale | Standard Deviation 1.27 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Induration(Lower limbs)(n=194,239,38,42) | -2.29 units on a scale | Standard Deviation 1.22 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | -0.71 units on a scale | Standard Deviation 1.13 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | -0.68 units on a scale | Standard Deviation 1.19 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Induration(Upper limbs)(n=305,327,69,72) | -1.94 units on a scale | Standard Deviation 1.24 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | -0.20 units on a scale | Standard Deviation 0.63 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | -2.07 units on a scale | Standard Deviation 1.28 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Head\Neck)(n=369,367,73,76) | -0.14 units on a scale | Standard Deviation 0.51 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | -2.52 units on a scale | Standard Deviation 1.17 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | -0.36 units on a scale | Standard Deviation 0.82 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Induration(Upper limbs)(n=340,345,74,76) | -0.70 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | -0.36 units on a scale | Standard Deviation 0.69 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Induration(Upper limbs)(n=369,367,73,76) | -0.33 units on a scale | Standard Deviation 0.62 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | -0.51 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | -2.11 units on a scale | Standard Deviation 1.18 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Head\Neck)(n=363,366,74,75) | -0.29 units on a scale | Standard Deviation 0.71 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | -0.26 units on a scale | Standard Deviation 0.62 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | -0.53 units on a scale | Standard Deviation 1.06 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 2:Scaling(Trunk)(n=369,367,73,76) | -0.32 units on a scale | Standard Deviation 0.66 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | -2.33 units on a scale | Standard Deviation 1.32 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Scaling(Trunk)(n=354,356,74,76) | -0.46 units on a scale | Standard Deviation 0.99 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | -0.62 units on a scale | Standard Deviation 1.23 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | -1.72 units on a scale | Standard Deviation 1.22 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 8:Induration(Head\Neck)(n=354,356,74,76) | -0.36 units on a scale | Standard Deviation 0.87 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | -2.55 units on a scale | Standard Deviation 1.09 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | -1.28 units on a scale | Standard Deviation 1.24 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | -1.95 units on a scale | Standard Deviation 1.06 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | -0.56 units on a scale | Standard Deviation 0.84 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Scaling(Trunk)(n=347,348,74,76) | -0.50 units on a scale | Standard Deviation 1.03 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | -1.64 units on a scale | Standard Deviation 1.19 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | -1.30 units on a scale | Standard Deviation 1.06 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | -0.36 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Induration(Head\Neck)(n=347,348,74,76) | -0.34 units on a scale | Standard Deviation 0.93 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | -1.76 units on a scale | Standard Deviation 1.29 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 4:Induration(Upper limbs)(n=363,366,74,75) | -0.44 units on a scale | Standard Deviation 0.66 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | -0.57 units on a scale | Standard Deviation 1.1 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Scaling(Trunk)(n=340,345,74,76) | -0.66 units on a scale | Standard Deviation 1.09 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | -2.00 units on a scale | Standard Deviation 1.23 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | -0.58 units on a scale | Standard Deviation 0.93 |
Secondary
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Baseline, Week 2, 4, 8,12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. N (number of participants analyzed) signifies the unique participants in the longitudinal model.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -16.50 units on a scale | Standard Error 0.41 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -15.54 units on a scale | Standard Error 0.41 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -15.40 units on a scale | Standard Error 0.47 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -13.35 units on a scale | Standard Error 0.42 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -11.68 units on a scale | Standard Error 0.4 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -7.87 units on a scale | Standard Error 0.34 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -15.84 units on a scale | Standard Error 0.46 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -14.23 units on a scale | Standard Error 0.44 |
| CP-690,550 5mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -4.09 units on a scale | Standard Error 0.28 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -16.44 units on a scale | Standard Error 0.44 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -17.65 units on a scale | Standard Error 0.41 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -17.36 units on a scale | Standard Error 0.4 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -9.47 units on a scale | Standard Error 0.34 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -4.94 units on a scale | Standard Error 0.28 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -13.70 units on a scale | Standard Error 0.4 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -16.42 units on a scale | Standard Error 0.45 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -16.98 units on a scale | Standard Error 0.45 |
| CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -15.56 units on a scale | Standard Error 0.42 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -5.94 units on a scale | Standard Error 0.96 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -1.04 units on a scale | Standard Error 0.62 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -3.09 units on a scale | Standard Error 0.76 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -5.11 units on a scale | Standard Error 0.89 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -5.46 units on a scale | Standard Error 0.92 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -11.90 units on a scale | Standard Error 0.88 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -15.08 units on a scale | Standard Error 0.89 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -14.33 units on a scale | Standard Error 0.98 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -13.92 units on a scale | Standard Error 1.02 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -17.14 units on a scale | Standard Error 0.89 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -5.10 units on a scale | Standard Error 0.91 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -4.23 units on a scale | Standard Error 0.87 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -16.16 units on a scale | Standard Error 0.99 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -16.42 units on a scale | Standard Error 0.96 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -3.65 units on a scale | Standard Error 0.75 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -13.12 units on a scale | Standard Error 0.87 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -5.80 units on a scale | Standard Error 0.95 |
| Placebo, Then CP-690,550 10 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -2.87 units on a scale | Standard Error 0.61 |
Secondary
Dermatology Life Quality Index (DLQI) Score
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Baseline (n=376,371,74,76) | 13.22 units on a scale | Standard Deviation 7.21 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 2 (n=369,367,73,76) | 9.07 units on a scale | Standard Deviation 6.51 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 4 (n=362,365,74,75) | 7.54 units on a scale | Standard Deviation 6.4 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 8 (n=352,354,74,76) | 6.44 units on a scale | Standard Deviation 6.35 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 12 (n=346,346,74,76) | 5.91 units on a scale | Standard Deviation 6.29 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 16 (n=338,342,74,76) | 5.53 units on a scale | Standard Deviation 5.93 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 20 (n=327,338,74,76) | 4.82 units on a scale | Standard Deviation 5.46 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 28 (n=301,324,68,70) | 4.50 units on a scale | Standard Deviation 5.19 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 40 (n=210,256,46,54) | 3.27 units on a scale | Standard Deviation 4.71 |
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Score | Week 52 (n=194,238,38,42) | 3.25 units on a scale | Standard Deviation 4.48 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 4 (n=362,365,74,75) | 5.70 units on a scale | Standard Deviation 5.48 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 40 (n=210,256,46,54) | 2.32 units on a scale | Standard Deviation 4 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 8 (n=352,354,74,76) | 4.50 units on a scale | Standard Deviation 5.37 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 12 (n=346,346,74,76) | 3.72 units on a scale | Standard Deviation 5.03 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 16 (n=338,342,74,76) | 3.55 units on a scale | Standard Deviation 4.93 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 20 (n=327,338,74,76) | 3.29 units on a scale | Standard Deviation 4.8 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 52 (n=194,238,38,42) | 2.21 units on a scale | Standard Deviation 3.87 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 28 (n=301,324,68,70) | 2.97 units on a scale | Standard Deviation 4.65 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Baseline (n=376,371,74,76) | 12.69 units on a scale | Standard Deviation 7.18 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 2 (n=369,367,73,76) | 8.02 units on a scale | Standard Deviation 6.25 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 28 (n=301,324,68,70) | 3.78 units on a scale | Standard Deviation 5.22 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 20 (n=327,338,74,76) | 4.91 units on a scale | Standard Deviation 5.33 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 52 (n=194,238,38,42) | 4.32 units on a scale | Standard Deviation 5.85 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Baseline (n=376,371,74,76) | 13.05 units on a scale | Standard Deviation 7.09 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 8 (n=352,354,74,76) | 8.99 units on a scale | Standard Deviation 6.91 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 16 (n=338,342,74,76) | 8.95 units on a scale | Standard Deviation 8.12 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 40 (n=210,256,46,54) | 4.30 units on a scale | Standard Deviation 6.5 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 2 (n=369,367,73,76) | 10.37 units on a scale | Standard Deviation 7.09 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 12 (n=346,346,74,76) | 8.28 units on a scale | Standard Deviation 6.74 |
| Placebo | Dermatology Life Quality Index (DLQI) Score | Week 4 (n=362,365,74,75) | 9.61 units on a scale | Standard Deviation 7.42 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 12 (n=346,346,74,76) | 10.25 units on a scale | Standard Deviation 6.91 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 28 (n=301,324,68,70) | 4.29 units on a scale | Standard Deviation 6.2 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 16 (n=338,342,74,76) | 10.03 units on a scale | Standard Deviation 7.33 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 52 (n=194,238,38,42) | 2.95 units on a scale | Standard Deviation 5.07 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 20 (n=327,338,74,76) | 5.97 units on a scale | Standard Deviation 6.07 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 2 (n=369,367,73,76) | 9.51 units on a scale | Standard Deviation 5.86 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 4 (n=362,365,74,75) | 9.47 units on a scale | Standard Deviation 6.45 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 8 (n=352,354,74,76) | 9.68 units on a scale | Standard Deviation 6.45 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Baseline (n=376,371,74,76) | 12.12 units on a scale | Standard Deviation 7.01 |
| Placebo, Then CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Score | Week 40 (n=210,256,46,54) | 2.94 units on a scale | Standard Deviation 4.85 |
Secondary
Dermatology Life Quality Index (DLQI) Total Score
The DLQI is a 10-item general dermatology questionnaire that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CP-690,550 5mg | Dermatology Life Quality Index (DLQI) Total Score | 13.22 units on a scale | Standard Deviation 7.21 |
| CP-690,550 10 mg | Dermatology Life Quality Index (DLQI) Total Score | 12.69 units on a scale | Standard Deviation 7.18 |
| Placebo | Dermatology Life Quality Index (DLQI) Total Score | 13.19 units on a scale | Standard Deviation 7.35 |
Secondary
Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Week 16, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 40 (n=210,256,46,54) | 0.90 units on a scale | Standard Deviation 0.13 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 16 (n=337,340,74,76) | 0.85 units on a scale | Standard Deviation 0.16 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 52 (n=194,237,38,42) | 0.89 units on a scale | Standard Deviation 0.12 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 28 (n=300,322,68,72) | 0.86 units on a scale | Standard Deviation 0.16 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Baseline (n=376,372,74,76) | 0.76 units on a scale | Standard Deviation 0.2 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 28 (n=300,322,68,72) | 0.88 units on a scale | Standard Deviation 0.15 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 40 (n=210,256,46,54) | 0.91 units on a scale | Standard Deviation 0.12 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 52 (n=194,237,38,42) | 0.89 units on a scale | Standard Deviation 0.14 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 16 (n=337,340,74,76) | 0.88 units on a scale | Standard Deviation 0.14 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Baseline (n=376,372,74,76) | 0.78 units on a scale | Standard Deviation 0.18 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 28 (n=300,322,68,72) | 0.88 units on a scale | Standard Deviation 0.15 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Baseline (n=376,372,74,76) | 0.79 units on a scale | Standard Deviation 0.15 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 16 (n=337,340,74,76) | 0.82 units on a scale | Standard Deviation 0.17 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 40 (n=210,256,46,54) | 0.91 units on a scale | Standard Deviation 0.1 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 52 (n=194,237,38,42) | 0.90 units on a scale | Standard Deviation 0.1 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 40 (n=210,256,46,54) | 0.88 units on a scale | Standard Deviation 0.18 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 16 (n=337,340,74,76) | 0.80 units on a scale | Standard Deviation 0.2 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Baseline (n=376,372,74,76) | 0.80 units on a scale | Standard Deviation 0.19 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 28 (n=300,322,68,72) | 0.86 units on a scale | Standard Deviation 0.16 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Health State Profile Utility Score | Week 52 (n=194,237,38,42) | 0.87 units on a scale | Standard Deviation 0.17 |
Secondary
Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline,Week 16, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 40 (n=210,255,46,54) | 81.40 mm | Standard Deviation 17.42 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 16 (n=337,339,74,76) | 76.19 mm | Standard Deviation 18.8 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 52 (n=195,238,38,42) | 81.95 mm | Standard Deviation 15.91 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 28 (n=300,322,69,72) | 78.48 mm | Standard Deviation 17.46 |
| CP-690,550 5mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Baseline (n=373,372,74,76) | 65.83 mm | Standard Deviation 24.04 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 28 (n=300,322,69,72) | 80.65 mm | Standard Deviation 15.31 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 40 (n=210,255,46,54) | 82.27 mm | Standard Deviation 15.69 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 52 (n=195,238,38,42) | 81.48 mm | Standard Deviation 15.53 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 16 (n=337,339,74,76) | 78.43 mm | Standard Deviation 17.59 |
| CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Baseline (n=373,372,74,76) | 67.38 mm | Standard Deviation 24.21 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 28 (n=300,322,69,72) | 77.00 mm | Standard Deviation 20.77 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Baseline (n=373,372,74,76) | 63.82 mm | Standard Deviation 23.66 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 16 (n=337,339,74,76) | 72.24 mm | Standard Deviation 20.76 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 40 (n=210,255,46,54) | 79.70 mm | Standard Deviation 19.17 |
| Placebo | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 52 (n=195,238,38,42) | 78.00 mm | Standard Deviation 19.11 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 40 (n=210,255,46,54) | 82.78 mm | Standard Deviation 18.58 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 16 (n=337,339,74,76) | 70.14 mm | Standard Deviation 22.19 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Baseline (n=373,372,74,76) | 65.05 mm | Standard Deviation 25.63 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 28 (n=300,322,69,72) | 77.53 mm | Standard Deviation 17.49 |
| Placebo, Then CP-690,550 10 mg | Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) | Week 52 (n=195,238,38,42) | 81.52 mm | Standard Deviation 20.6 |
Secondary
Family Dermatology Life Quality Index (FDLQI) Score
The FDLQI is a 10-item questionnaire that examine the impact of health-related quality of life issues associated with living with a person with a skin condition (example, emotional distress, personal relationships, reactions of other people, social life, caregiving) over the last month. The FDLQI need to be completed by a family member (for example, spouse or partner, parent) who currently lives with the participant. Each question is scored on a scale from 0 (Not at all/ Not relevant) to 3 (Very much). Total score is calculated by summing the score of each item resulting in a maximum score of '30' and a minimum score of '0'. Higher scores indicate greater impairment to quality of life. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.
Time frame: Baseline, Week 16, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. 'n' signifies participants evaluable at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Family Dermatology Life Quality Index (FDLQI) Score | Baseline (n=41,47,14,11) | 9.20 units on a scale | Standard Deviation 6.65 |
| CP-690,550 5mg | Family Dermatology Life Quality Index (FDLQI) Score | Week52 (n=13,12,4,4) | 3.08 units on a scale | Standard Deviation 5.22 |
| CP-690,550 5mg | Family Dermatology Life Quality Index (FDLQI) Score | Week 16 (n=36,32,11,9) | 4.17 units on a scale | Standard Deviation 4.48 |
| CP-690,550 10 mg | Family Dermatology Life Quality Index (FDLQI) Score | Baseline (n=41,47,14,11) | 9.57 units on a scale | Standard Deviation 6.78 |
| CP-690,550 10 mg | Family Dermatology Life Quality Index (FDLQI) Score | Week52 (n=13,12,4,4) | 2.33 units on a scale | Standard Deviation 2.9 |
| CP-690,550 10 mg | Family Dermatology Life Quality Index (FDLQI) Score | Week 16 (n=36,32,11,9) | 2.84 units on a scale | Standard Deviation 3.48 |
| Placebo | Family Dermatology Life Quality Index (FDLQI) Score | Week 16 (n=36,32,11,9) | 6.09 units on a scale | Standard Deviation 4.41 |
| Placebo | Family Dermatology Life Quality Index (FDLQI) Score | Baseline (n=41,47,14,11) | 8.07 units on a scale | Standard Deviation 6.26 |
| Placebo | Family Dermatology Life Quality Index (FDLQI) Score | Week52 (n=13,12,4,4) | 1.75 units on a scale | Standard Deviation 3.5 |
| Placebo, Then CP-690,550 10 mg | Family Dermatology Life Quality Index (FDLQI) Score | Baseline (n=41,47,14,11) | 6.27 units on a scale | Standard Deviation 4.5 |
| Placebo, Then CP-690,550 10 mg | Family Dermatology Life Quality Index (FDLQI) Score | Week52 (n=13,12,4,4) | 2.00 units on a scale | Standard Deviation 1.41 |
| Placebo, Then CP-690,550 10 mg | Family Dermatology Life Quality Index (FDLQI) Score | Week 16 (n=36,32,11,9) | 7.33 units on a scale | Standard Deviation 6.02 |
Secondary
Hospital Anxiety and Depression Scale (HADS) Score
HADS: 14-item questionnaire that screens for the presence of anxiety and depression symptoms. There are 7 items comprising the anxiety subscale and 7 items comprising the depression subscale. Each item has response options ranging from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total HADS score ranges from 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 8, 16, 28, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Anxiety subcale(n=376,371,74,76) | 7.05 units on a scale | Standard Deviation 4.14 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Depression subcale(n=376,371,74,76) | 6.00 units on a scale | Standard Deviation 4.42 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Anxiety subcale(n=351,354,74,76) | 5.65 units on a scale | Standard Deviation 4 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Depression subcale(n=351,354,74,76) | 4.68 units on a scale | Standard Deviation 3.91 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Anxiety(n=337,340,74,76) | 5.43 units on a scale | Standard Deviation 4.08 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Depression(n=337,340,74,76) | 4.36 units on a scale | Standard Deviation 4.06 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Anxiety(n=300,322,68,72) | 4.86 units on a scale | Standard Deviation 3.92 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Depression(n=300,322,68,72) | 4.03 units on a scale | Standard Deviation 3.97 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Anxiety(n=194,237,38,42) | 4.36 units on a scale | Standard Deviation 3.94 |
| CP-690,550 5mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Depression(n=194,237,38,42) | 3.62 units on a scale | Standard Deviation 3.84 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Anxiety subcale(n=351,354,74,76) | 5.15 units on a scale | Standard Deviation 3.59 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Anxiety(n=194,237,38,42) | 4.32 units on a scale | Standard Deviation 3.68 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Depression subcale(n=351,354,74,76) | 3.72 units on a scale | Standard Deviation 3.35 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Anxiety(n=337,340,74,76) | 5.18 units on a scale | Standard Deviation 4 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Depression(n=337,340,74,76) | 3.50 units on a scale | Standard Deviation 3.32 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Anxiety(n=300,322,68,72) | 4.71 units on a scale | Standard Deviation 3.85 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Depression(n=194,237,38,42) | 3.14 units on a scale | Standard Deviation 3.22 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Depression(n=300,322,68,72) | 3.20 units on a scale | Standard Deviation 3.29 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Anxiety subcale(n=376,371,74,76) | 6.94 units on a scale | Standard Deviation 4.36 |
| CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Depression subcale(n=376,371,74,76) | 5.64 units on a scale | Standard Deviation 4.16 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Depression(n=300,322,68,72) | 3.68 units on a scale | Standard Deviation 3.91 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Anxiety(n=300,322,68,72) | 4.96 units on a scale | Standard Deviation 4.26 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Depression(n=194,237,38,42) | 3.29 units on a scale | Standard Deviation 3.5 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Anxiety subcale(n=376,371,74,76) | 7.72 units on a scale | Standard Deviation 4.31 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Depression subcale(n=351,354,74,76) | 4.95 units on a scale | Standard Deviation 4.02 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Depression(n=337,340,74,76) | 4.49 units on a scale | Standard Deviation 4.2 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Anxiety(n=194,237,38,42) | 4.89 units on a scale | Standard Deviation 4.57 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Depression subcale(n=376,371,74,76) | 5.85 units on a scale | Standard Deviation 4.38 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Anxiety(n=337,340,74,76) | 5.43 units on a scale | Standard Deviation 3.8 |
| Placebo | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Anxiety subcale(n=351,354,74,76) | 6.45 units on a scale | Standard Deviation 3.81 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Anxiety(n=337,340,74,76) | 5.55 units on a scale | Standard Deviation 4.22 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Depression(n=300,322,68,72) | 4.65 units on a scale | Standard Deviation 3.82 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 16:Depression(n=337,340,74,76) | 5.21 units on a scale | Standard Deviation 3.94 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Depression(n=194,237,38,42) | 2.95 units on a scale | Standard Deviation 3.11 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 28:Anxiety(n=300,322,68,72) | 5.10 units on a scale | Standard Deviation 4.11 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Depression subcale(n=376,371,74,76) | 5.51 units on a scale | Standard Deviation 3.79 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Anxiety subcale(n=351,354,74,76) | 6.47 units on a scale | Standard Deviation 4.06 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 8:Depression subcale(n=351,354,74,76) | 5.03 units on a scale | Standard Deviation 3.75 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Baseline:Anxiety subcale(n=376,371,74,76) | 6.38 units on a scale | Standard Deviation 4.14 |
| Placebo, Then CP-690,550 10 mg | Hospital Anxiety and Depression Scale (HADS) Score | Week 52:Anxiety(n=194,237,38,42) | 4.10 units on a scale | Standard Deviation 3.53 |
Secondary
Itch Severity Item (ISI) Score
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate your worst itching due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms No itching (0) and Worst possible itching (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.
Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Baseline (n=364,361,74,71) | 5.70 units on a scale | Standard Deviation 2.65 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 2 (n=369,367,73,76) | 3.88 units on a scale | Standard Deviation 2.66 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 4 (n=364,365,74,75) | 3.22 units on a scale | Standard Deviation 2.61 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 8 (n=354,354,74,76) | 2.79 units on a scale | Standard Deviation 2.68 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 12 (n=347,349,74,76) | 2.55 units on a scale | Standard Deviation 2.75 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 16 (n=340,345,74,76) | 2.31 units on a scale | Standard Deviation 2.59 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 20 (n=327,338,74,76) | 2.06 units on a scale | Standard Deviation 2.52 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 28 (n=304,326,68,72) | 2.05 units on a scale | Standard Deviation 2.53 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week 40 (n=212,262,46,55) | 1.58 units on a scale | Standard Deviation 2.3 |
| CP-690,550 5mg | Itch Severity Item (ISI) Score | Week52 (n=194,238,38,42) | 1.62 units on a scale | Standard Deviation 2.31 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 4 (n=364,365,74,75) | 2.45 units on a scale | Standard Deviation 2.36 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 40 (n=212,262,46,55) | 1.34 units on a scale | Standard Deviation 2.01 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 8 (n=354,354,74,76) | 1.89 units on a scale | Standard Deviation 2.33 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 12 (n=347,349,74,76) | 1.77 units on a scale | Standard Deviation 2.38 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 16 (n=340,345,74,76) | 1.68 units on a scale | Standard Deviation 2.38 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 20 (n=327,338,74,76) | 1.44 units on a scale | Standard Deviation 2.16 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week52 (n=194,238,38,42) | 1.15 units on a scale | Standard Deviation 1.8 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 28 (n=304,326,68,72) | 1.52 units on a scale | Standard Deviation 2.21 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Baseline (n=364,361,74,71) | 5.51 units on a scale | Standard Deviation 2.64 |
| CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 2 (n=369,367,73,76) | 3.47 units on a scale | Standard Deviation 2.61 |
| Placebo | Itch Severity Item (ISI) Score | Week 28 (n=304,326,68,72) | 1.93 units on a scale | Standard Deviation 2.51 |
| Placebo | Itch Severity Item (ISI) Score | Week 20 (n=327,338,74,76) | 2.28 units on a scale | Standard Deviation 2.47 |
| Placebo | Itch Severity Item (ISI) Score | Week52 (n=194,238,38,42) | 1.82 units on a scale | Standard Deviation 2.55 |
| Placebo | Itch Severity Item (ISI) Score | Baseline (n=364,361,74,71) | 5.32 units on a scale | Standard Deviation 2.66 |
| Placebo | Itch Severity Item (ISI) Score | Week 8 (n=354,354,74,76) | 4.77 units on a scale | Standard Deviation 2.96 |
| Placebo | Itch Severity Item (ISI) Score | Week 16 (n=340,345,74,76) | 4.84 units on a scale | Standard Deviation 3.19 |
| Placebo | Itch Severity Item (ISI) Score | Week 40 (n=212,262,46,55) | 1.89 units on a scale | Standard Deviation 2.64 |
| Placebo | Itch Severity Item (ISI) Score | Week 2 (n=369,367,73,76) | 5.01 units on a scale | Standard Deviation 2.72 |
| Placebo | Itch Severity Item (ISI) Score | Week 12 (n=347,349,74,76) | 4.46 units on a scale | Standard Deviation 2.94 |
| Placebo | Itch Severity Item (ISI) Score | Week 4 (n=364,365,74,75) | 4.64 units on a scale | Standard Deviation 3.05 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 12 (n=347,349,74,76) | 5.01 units on a scale | Standard Deviation 2.95 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 28 (n=304,326,68,72) | 1.51 units on a scale | Standard Deviation 2.42 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 16 (n=340,345,74,76) | 5.17 units on a scale | Standard Deviation 3.07 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week52 (n=194,238,38,42) | 1.19 units on a scale | Standard Deviation 1.99 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 20 (n=327,338,74,76) | 2.42 units on a scale | Standard Deviation 2.43 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 2 (n=369,367,73,76) | 4.66 units on a scale | Standard Deviation 2.5 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 4 (n=364,365,74,75) | 4.83 units on a scale | Standard Deviation 2.64 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 8 (n=354,354,74,76) | 4.95 units on a scale | Standard Deviation 2.79 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Baseline (n=364,361,74,71) | 5.08 units on a scale | Standard Deviation 2.58 |
| Placebo, Then CP-690,550 10 mg | Itch Severity Item (ISI) Score | Week 40 (n=212,262,46,55) | 1.15 units on a scale | Standard Deviation 2.09 |
Secondary
Joint Pain Assessment (JPA) Score
The JPA assesses severity of joint pain. The JPA is a horizontal numeric rating scale. Participants were asked to select the number that best describes any joint pain that participant may have experienced over the past 24 hours with response options ranging from 0-no joint pain to 10-worst possible joint pain.
Time frame: Baseline, Week 8,16, 28, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Joint Pain Assessment (JPA) Score | Week 28 (n=300,320,68,72) | 2.25 units on a scale | Standard Deviation 2.64 |
| CP-690,550 5mg | Joint Pain Assessment (JPA) Score | Week 8 (n=351,354,74,76) | 2.50 units on a scale | Standard Deviation 2.56 |
| CP-690,550 5mg | Joint Pain Assessment (JPA) Score | Baseline (n=376,372,74,76) | 3.79 units on a scale | Standard Deviation 3.13 |
| CP-690,550 5mg | Joint Pain Assessment (JPA) Score | Week 16 (n=336,340,74,76) | 2.24 units on a scale | Standard Deviation 2.59 |
| CP-690,550 5mg | Joint Pain Assessment (JPA) Score | Week 52 (n=193,235,38,42) | 1.88 units on a scale | Standard Deviation 2.41 |
| CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 52 (n=193,235,38,42) | 1.74 units on a scale | Standard Deviation 2.3 |
| CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 16 (n=336,340,74,76) | 1.95 units on a scale | Standard Deviation 2.41 |
| CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Baseline (n=376,372,74,76) | 3.44 units on a scale | Standard Deviation 3.09 |
| CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 8 (n=351,354,74,76) | 2.22 units on a scale | Standard Deviation 2.58 |
| CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 28 (n=300,320,68,72) | 1.78 units on a scale | Standard Deviation 2.4 |
| Placebo | Joint Pain Assessment (JPA) Score | Week 8 (n=351,354,74,76) | 2.86 units on a scale | Standard Deviation 2.91 |
| Placebo | Joint Pain Assessment (JPA) Score | Week 16 (n=336,340,74,76) | 2.88 units on a scale | Standard Deviation 2.93 |
| Placebo | Joint Pain Assessment (JPA) Score | Week 28 (n=300,320,68,72) | 2.15 units on a scale | Standard Deviation 2.62 |
| Placebo | Joint Pain Assessment (JPA) Score | Baseline (n=376,372,74,76) | 3.45 units on a scale | Standard Deviation 2.89 |
| Placebo | Joint Pain Assessment (JPA) Score | Week 52 (n=193,235,38,42) | 2.00 units on a scale | Standard Deviation 2.63 |
| Placebo, Then CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 8 (n=351,354,74,76) | 3.14 units on a scale | Standard Deviation 3 |
| Placebo, Then CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 28 (n=300,320,68,72) | 2.26 units on a scale | Standard Deviation 2.64 |
| Placebo, Then CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 16 (n=336,340,74,76) | 3.21 units on a scale | Standard Deviation 3.16 |
| Placebo, Then CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Baseline (n=376,372,74,76) | 2.96 units on a scale | Standard Deviation 3.05 |
| Placebo, Then CP-690,550 10 mg | Joint Pain Assessment (JPA) Score | Week 52 (n=193,235,38,42) | 1.64 units on a scale | Standard Deviation 2.59 |
Secondary
Nail Psoriasis Severity Index (NAPSI) Score
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.'n' signifies participants evaluable at specified time point for each arm.
Time frame: Baseline, Week 8, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP non-compliance. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 52 (n=108,137,21,30) | 9.06 units on a scale | Standard Deviation 13.43 |
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 40 (n=118,148,26,39) | 10.11 units on a scale | Standard Deviation 15.71 |
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 16 (n=218,205,43,55) | 17.17 units on a scale | Standard Deviation 16.86 |
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 8 (n=226,214,43,55) | 22.36 units on a scale | Standard Deviation 19.83 |
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Baseline (n=240,226,43,55) | 27.31 units on a scale | Standard Deviation 20.45 |
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 28 (n=193,197,40,53) | 11.77 units on a scale | Standard Deviation 15.29 |
| CP-690,550 5mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 20 (n=208,206,43,55) | 15.03 units on a scale | Standard Deviation 16.97 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Baseline (n=240,226,43,55) | 26.22 units on a scale | Standard Deviation 20.35 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 40 (n=118,148,26,39) | 7.95 units on a scale | Standard Deviation 13.57 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 52 (n=108,137,21,30) | 7.92 units on a scale | Standard Deviation 14.32 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 8 (n=226,214,43,55) | 21.88 units on a scale | Standard Deviation 19.29 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 20 (n=208,206,43,55) | 14.02 units on a scale | Standard Deviation 16.7 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 16 (n=218,205,43,55) | 16.58 units on a scale | Standard Deviation 18.13 |
| CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 28 (n=193,197,40,53) | 11.78 units on a scale | Standard Deviation 15.9 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Week 52 (n=108,137,21,30) | 5.29 units on a scale | Standard Deviation 7.12 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Baseline (n=240,226,43,55) | 25.40 units on a scale | Standard Deviation 17.6 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Week 8 (n=226,214,43,55) | 21.86 units on a scale | Standard Deviation 17.24 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Week 16 (n=218,205,43,55) | 22.53 units on a scale | Standard Deviation 18.96 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Week 20 (n=208,206,43,55) | 21.44 units on a scale | Standard Deviation 18.32 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Week 28 (n=193,197,40,53) | 15.93 units on a scale | Standard Deviation 16.06 |
| Placebo | Nail Psoriasis Severity Index (NAPSI) Score | Week 40 (n=118,148,26,39) | 7.73 units on a scale | Standard Deviation 11.8 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 16 (n=218,205,43,55) | 25.69 units on a scale | Standard Deviation 18.37 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 40 (n=118,148,26,39) | 11.31 units on a scale | Standard Deviation 13.41 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 28 (n=193,197,40,53) | 17.77 units on a scale | Standard Deviation 15.9 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 8 (n=226,214,43,55) | 25.75 units on a scale | Standard Deviation 18.29 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Baseline (n=240,226,43,55) | 26.78 units on a scale | Standard Deviation 18.67 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 20 (n=208,206,43,55) | 24.29 units on a scale | Standard Deviation 17.3 |
| Placebo, Then CP-690,550 10 mg | Nail Psoriasis Severity Index (NAPSI) Score | Week 52 (n=108,137,21,30) | 7.53 units on a scale | Standard Deviation 9.35 |
Secondary
Number of Affected Nails
Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Total number of psoriasis affected nails (presence of psoriatic manifestations on the nail matrix / nail bed) were assessed and reported. 'N' (number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.
Time frame: Baseline, Week 8, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP non-compliance. 'n' signifies participants evaluable at specified time point for each arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Number of Affected Nails | Baseline (n=240,226,43,55) | 7.45 nails | Standard Deviation 3.03 |
| CP-690,550 5mg | Number of Affected Nails | Week 40 (n=118,148,26,39) | 3.79 nails | Standard Deviation 3.75 |
| CP-690,550 5mg | Number of Affected Nails | Week 28 (n=193,197,40,53) | 4.42 nails | Standard Deviation 3.74 |
| CP-690,550 5mg | Number of Affected Nails | Week 8 (n=226,214,43,55) | 6.50 nails | Standard Deviation 3.51 |
| CP-690,550 5mg | Number of Affected Nails | Week 52 (n=108,137,21,30) | 3.63 nails | Standard Deviation 3.7 |
| CP-690,550 5mg | Number of Affected Nails | Week 16 (n=218,204,43,55) | 5.83 nails | Standard Deviation 3.58 |
| CP-690,550 5mg | Number of Affected Nails | Week 20 (n=207,206,43,55) | 5.19 nails | Standard Deviation 3.66 |
| CP-690,550 10 mg | Number of Affected Nails | Week 40 (n=118,148,26,39) | 3.03 nails | Standard Deviation 3.53 |
| CP-690,550 10 mg | Number of Affected Nails | Week 20 (n=207,206,43,55) | 4.86 nails | Standard Deviation 3.89 |
| CP-690,550 10 mg | Number of Affected Nails | Week 16 (n=218,204,43,55) | 5.37 nails | Standard Deviation 3.91 |
| CP-690,550 10 mg | Number of Affected Nails | Week 28 (n=193,197,40,53) | 4.23 nails | Standard Deviation 3.85 |
| CP-690,550 10 mg | Number of Affected Nails | Week 52 (n=108,137,21,30) | 2.85 nails | Standard Deviation 3.73 |
| CP-690,550 10 mg | Number of Affected Nails | Week 8 (n=226,214,43,55) | 6.65 nails | Standard Deviation 3.61 |
| CP-690,550 10 mg | Number of Affected Nails | Baseline (n=240,226,43,55) | 7.23 nails | Standard Deviation 3.2 |
| Placebo | Number of Affected Nails | Week 20 (n=207,206,43,55) | 6.44 nails | Standard Deviation 3.8 |
| Placebo | Number of Affected Nails | Baseline (n=240,226,43,55) | 7.21 nails | Standard Deviation 2.77 |
| Placebo | Number of Affected Nails | Week 8 (n=226,214,43,55) | 6.98 nails | Standard Deviation 3.11 |
| Placebo | Number of Affected Nails | Week 16 (n=218,204,43,55) | 6.79 nails | Standard Deviation 3.53 |
| Placebo | Number of Affected Nails | Week 28 (n=193,197,40,53) | 5.38 nails | Standard Deviation 4.11 |
| Placebo | Number of Affected Nails | Week 40 (n=118,148,26,39) | 3.12 nails | Standard Deviation 3.56 |
| Placebo | Number of Affected Nails | Week 52 (n=108,137,21,30) | 2.86 nails | Standard Deviation 3.45 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Week 16 (n=218,204,43,55) | 7.56 nails | Standard Deviation 3.02 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Week 52 (n=108,137,21,30) | 3.67 nails | Standard Deviation 3.74 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Week 40 (n=118,148,26,39) | 4.41 nails | Standard Deviation 3.89 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Week 8 (n=226,214,43,55) | 7.56 nails | Standard Deviation 2.99 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Baseline (n=240,226,43,55) | 7.36 nails | Standard Deviation 3.08 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Week 28 (n=193,197,40,53) | 6.40 nails | Standard Deviation 3.62 |
| Placebo, Then CP-690,550 10 mg | Number of Affected Nails | Week 20 (n=207,206,43,55) | 7.42 nails | Standard Deviation 2.99 |
Secondary
Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 28 | 52.13 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 20 | 49.47 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 52 | 42.02 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 12 | 38.56 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 8 | 24.47 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 4 | 7.45 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 40 | 46.01 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 16 | 46.01 percentage of participants |
| CP-690,550 5mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 2 | 1.33 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 16 | 59.63 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 28 | 66.31 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 20 | 62.03 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 4 | 14.17 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 2 | 1.87 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 8 | 39.30 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 52 | 52.41 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 40 | 60.43 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 12 | 53.48 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 16 | 16.22 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 2 | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 4 | 5.41 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 8 | 8.11 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 12 | 13.51 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 20 | 32.43 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 28 | 52.70 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 40 | 50.00 percentage of participants |
| Placebo | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 52 | 41.89 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 28 | 64.47 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 12 | 6.58 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 8 | 5.26 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 52 | 44.74 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 40 | 59.21 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 4 | 3.95 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 20 | 38.16 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 16 | 11.84 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Response | Week 2 | 0.00 percentage of participants |
Secondary
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.
Time frame: Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16 | 24.47 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16 | 38.77 percentage of participants |
| Placebo | Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 16 | 5.18 percentage of participants |
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [3.48, 17.31]Cochran-Mantel-Haenszel
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [8.08, 46.22]Cochran-Mantel-Haenszel
p-value: <0.000195% CI: [7.72, 20.88]Normal Approximation
Secondary
Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.
Time frame: Week 8,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 8 | 7.92 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 16 | 10.42 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 20 | 14.17 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 28 | 18.75 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 40 | 17.08 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 52 | 17.08 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 52 | 29.65 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 28 | 25.22 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 8 | 7.52 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 20 | 21.68 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 16 | 16.37 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 40 | 25.66 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 16 | 11.63 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 20 | 16.28 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 28 | 23.26 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 52 | 20.93 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 40 | 23.26 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 8 | 2.33 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 40 | 20.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 52 | 20.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 16 | 5.45 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 28 | 12.73 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 8 | 1.82 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 100 (NAPSI 100) Response | Week 20 | 3.64 percentage of participants |
Secondary
Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported. N(number of participants analyzed) signifies participants (with baseline nail psoriasis) who were evaluable for this measure.
Time frame: Week 8, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 8 | 10.83 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 16 | 18.75 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 20 | 24.17 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 28 | 34.58 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 40 | 24.58 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 52 | 23.75 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 52 | 40.71 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 28 | 39.82 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 8 | 11.95 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 20 | 33.19 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 16 | 26.99 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 40 | 40.71 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 16 | 16.28 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 20 | 23.26 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 28 | 32.56 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 52 | 39.53 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 40 | 44.19 percentage of participants |
| Placebo | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 8 | 6.98 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 40 | 38.18 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 52 | 29.09 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 16 | 5.45 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 28 | 18.18 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 8 | 1.82 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Nail Psoriasis Severity Index 75 (NAPSI 75) Response | Week 20 | 7.27 percentage of participants |
Secondary
Percentage of Participants With Patient Global Assessment (PtGA) Scale Response
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear \[no psoriasis\]; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Clear(n=337,342,74,75) | 6.2 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Severe(n=346,345,74,76) | 13.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week4:Moderate(n=363,365,74,75) | 46.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Almost Clear(n=376,372,74,76) | 0.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Moderate(n=346,345,74,76) | 26.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Mild(n=346,345,74,76) | 24.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Severe(n=363,365,74,75) | 23.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Moderate(n=210,255,46,54) | 12.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Almost Clear(n=346,345,74,76) | 30.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Clear(n=346,345,74,76) | 4.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Clear(n=352,354,74,76) | 1.7 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Mild(n=210,255,46,54) | 22.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Severe(n=352,354,74,76) | 16.8 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Moderate(n=352,354,74,76) | 32.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Almost clear(n=352,354,74,76) | 19.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Severe(n=376,372,74,76) | 62.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Mild(n=352,354,74,76) | 29.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Severe(n=194,238,38,42) | 3.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40: Almost Clear(n=210,255,46,54) | 40.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Clear(n=210,255,46,54) | 21.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Clear(n=369,366,73,76) | 0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Mild(n=194,238,38,42) | 24.2 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Severe(n=300,324,68,72) | 6.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Moderate(n=300,324,68,72) | 22.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Almost Clear(n=369,366,73,76) | 2.2 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Clear(n=376,372,74,76) | 0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Mild(n=300,324,68,72) | 26.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Almost Clear(n=300,324,68,72) | 34.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Mild(n=369,366,73,76) | 13.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Almost Clear(n=194,238,38,42) | 44.8 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Clear(n=300,324,68,72) | 11.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Severe(n=327,338,73,76) | 8.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Moderate(n=369,366,73,76) | 49.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Mild(n=376,372,74,76) | 4.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Moderate(n=327,338,73,76) | 23.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Mild(n=327,338,73,76) | 25.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Severe(n=369,366,73,76) | 34.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Moderate(n=194,238,38,42) | 12.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Almost Clear(n=327,338,73,76) | 33.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Clear(n=327,338,73,76) | 8.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Clear(n=363,365,74,75) | 0.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Clear(n=194,238,38,42) | 14.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Severe(n=n=337,342,74,75) | 13.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Moderate(n=n=337,342,74,75) | 21.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Almost clear(n=363,365,74,75) | 7.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Severe(n=210,255,46,54) | 3.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Mild(n=n=337,342,74,75) | 27.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Almost clear(n=337,342,74,75) | 30.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Mild(n=363,365,74,75) | 22.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Moderate(n=376,372,74,76) | 33.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Almost Clear(n=369,366,73,76) | 2.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Clear(n=376,372,74,76) | 0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Almost Clear(n=376,372,74,76) | 0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Mild(n=376,372,74,76) | 3.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Moderate(n=376,372,74,76) | 32.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Severe(n=376,372,74,76) | 64.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Clear(n=369,366,73,76) | 0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Mild(n=369,366,73,76) | 21.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Moderate(n=369,366,73,76) | 45.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Severe(n=369,366,73,76) | 31.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Clear(n=363,365,74,75) | 0.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Almost clear(n=363,365,74,75) | 13.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Mild(n=363,365,74,75) | 35.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week4:Moderate(n=363,365,74,75) | 33.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Severe(n=363,365,74,75) | 17.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Clear(n=352,354,74,76) | 4.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Almost clear(n=352,354,74,76) | 32.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Mild(n=352,354,74,76) | 30.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Moderate(n=352,354,74,76) | 22.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Severe(n=352,354,74,76) | 9.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Clear(n=346,345,74,76) | 11.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Almost Clear(n=346,345,74,76) | 43.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Mild(n=346,345,74,76) | 19.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Moderate(n=346,345,74,76) | 18.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Severe(n=346,345,74,76) | 7.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Clear(n=337,342,74,75) | 14.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Almost clear(n=337,342,74,75) | 41.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Mild(n=n=337,342,74,75) | 21.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Moderate(n=n=337,342,74,75) | 16.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Severe(n=n=337,342,74,75) | 5.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Clear(n=327,338,73,76) | 15.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Almost Clear(n=327,338,73,76) | 43.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Mild(n=327,338,73,76) | 21.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Moderate(n=327,338,73,76) | 12.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Severe(n=327,338,73,76) | 6.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Clear(n=300,324,68,72) | 21.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Almost Clear(n=300,324,68,72) | 43.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Mild(n=300,324,68,72) | 17.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Moderate(n=300,324,68,72) | 12.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Severe(n=300,324,68,72) | 5.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Clear(n=210,255,46,54) | 26.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40: Almost Clear(n=210,255,46,54) | 45.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Mild(n=210,255,46,54) | 16.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Moderate(n=210,255,46,54) | 8.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Severe(n=210,255,46,54) | 2.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Clear(n=194,238,38,42) | 26.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Almost Clear(n=194,238,38,42) | 45.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Mild(n=194,238,38,42) | 16.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Moderate(n=194,238,38,42) | 8.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Severe(n=194,238,38,42) | 2.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Mild(n=363,365,74,75) | 10.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Clear(n=337,342,74,75) | 6.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Almost clear(n=337,342,74,75) | 2.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Almost clear(n=363,365,74,75) | 5.4 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Moderate(n=194,238,38,42) | 13.2 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Mild(n=n=337,342,74,75) | 20.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Severe(n=210,255,46,54) | 8.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Moderate(n=n=337,342,74,75) | 39.2 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Clear(n=363,365,74,75) | 0 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Severe(n=n=337,342,74,75) | 31.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Mild(n=376,372,74,76) | 2.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Clear(n=327,338,73,76) | 9.6 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Severe(n=369,366,73,76) | 45.2 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Almost Clear(n=327,338,73,76) | 13.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Clear(n=194,238,38,42) | 26.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Mild(n=327,338,73,76) | 39.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Moderate(n=369,366,73,76) | 41.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Moderate(n=327,338,73,76) | 28.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Severe(n=327,338,73,76) | 8.2 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Mild(n=369,366,73,76) | 12.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Clear(n=376,372,74,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Clear(n=300,324,68,72) | 19.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Almost Clear(n=194,238,38,42) | 26.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Almost Clear(n=300,324,68,72) | 36.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Almost Clear(n=369,366,73,76) | 1.4 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Mild(n=300,324,68,72) | 17.6 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Almost Clear(n=376,372,74,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Moderate(n=300,324,68,72) | 17.6 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Clear(n=369,366,73,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Severe(n=300,324,68,72) | 8.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Mild(n=194,238,38,42) | 28.9 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Clear(n=210,255,46,54) | 21.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Severe(n=376,372,74,76) | 55.4 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40: Almost Clear(n=210,255,46,54) | 37.0 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Almost clear(n=352,354,74,76) | 1.4 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Mild(n=352,354,74,76) | 16.2 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Moderate(n=352,354,74,76) | 47.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Clear(n=352,354,74,76) | 4.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Severe(n=352,354,74,76) | 31.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Mild(n=210,255,46,54) | 19.6 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Clear(n=346,345,74,76) | 2.7 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Severe(n=363,365,74,75) | 37.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Almost Clear(n=346,345,74,76) | 8.1 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Moderate(n=376,372,74,76) | 41.9 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Mild(n=346,345,74,76) | 20.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week4:Moderate(n=363,365,74,75) | 45.9 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Severe(n=194,238,38,42) | 5.3 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Moderate(n=346,345,74,76) | 37.8 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Moderate(n=210,255,46,54) | 13.0 percentage of participants |
| Placebo | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Severe(n=346,345,74,76) | 31.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Moderate(n=352,354,74,76) | 40.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Moderate(n=210,255,46,54) | 9.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Mild(n=300,324,68,72) | 18.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Clear(n=337,342,74,75) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Almost clear(n=363,365,74,75) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Mild(n=376,372,74,76) | 2.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Clear(n=369,366,73,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Almost clear(n=337,342,74,75) | 2.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Almost Clear(n=346,345,74,76) | 2.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Clear(n=376,372,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Moderate(n=300,324,68,72) | 18.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Mild(n=n=337,342,74,75) | 14.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Clear(n=363,365,74,75) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week4:Moderate(n=363,365,74,75) | 41.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Severe(n=194,238,38,42) | 7.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Moderate(n=n=337,342,74,75) | 34.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Severe(n=352,354,74,76) | 48.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Severe(n=210,255,46,54) | 7.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Severe(n=300,324,68,72) | 8.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 16:Severe(n=n=337,342,74,75) | 48.0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 2:Severe(n=369,366,73,76) | 50.0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Severe(n=376,372,74,76) | 63.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Severe(n=363,365,74,75) | 46.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Clear(n=327,338,73,76) | 1.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 4:Mild(n=363,365,74,75) | 12.0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Moderate(n=194,238,38,42) | 7.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Clear(n=210,255,46,54) | 20.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Almost Clear(n=327,338,73,76) | 18.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Moderate(n=369,366,73,76) | 42.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Severe(n=346,345,74,76) | 46.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Mild(n=194,238,38,42) | 11.9 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Mild(n=327,338,73,76) | 34.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Clear(n=346,345,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Clear(n=194,238,38,42) | 21.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Almost clear(n=352,354,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Moderate(n=327,338,73,76) | 30.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Mild(n=369,366,73,76) | 7.9 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Almost Clear(n=376,372,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Mild(n=346,345,74,76) | 7.9 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 20:Severe(n=327,338,73,76) | 15.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40: Almost Clear(n=210,255,46,54) | 50.0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 40:Mild(n=210,255,46,54) | 13.0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Mild(n=352,354,74,76) | 10.5 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Clear(n=300,324,68,72) | 12.5 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week2:Almost Clear(n=369,366,73,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 8:Clear(n=352,354,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Baseline:Moderate(n=376,372,74,76) | 34.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 28:Almost Clear(n=300,324,68,72) | 43.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 12:Moderate(n=346,345,74,76) | 43.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Global Assessment (PtGA) Scale Response | Week 52:Almost Clear(n=194,238,38,42) | 52.4 percentage of participants |
Secondary
Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response
The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from very dissatisfied to very satisfied with the study treatment.
Time frame: Week 16, 28, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very satisfied(n=337,339,74,76) | 48.4 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat satisfied(n=337,339,74,76) | 24.9 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly satisfied(n=337,339,74,76) | 8.0 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week16:Not satisfied/dissatisfied(n=337,339,74,76) | 4.7 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly dissatisfied(n=337,339,74,76) | 3.3 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat dissatisfied(n=337,339,74,76) | 5.3 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very dissatisfied(n=337,339,74,76) | 5.3 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very satisfied(n=300,320,68,72) | 48.7 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat satisfied(n=300,320,68,72) | 28.0 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly satisfied(n=300,320,68,72) | 11.0 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week28:Not satisfied/dissatisfied(n=300,320,68,72) | 3.0 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly dissatisfied(n=300,320,68,72) | 3.3 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat dissatisfied(n=300,320,68,72) | 2.7 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very dissatisfied(n=300,320,68,72) | 3.3 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very satisfied(n=194,237,38,42) | 57.7 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat satisfied(n=194,237,38,42) | 29.4 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly satisfied(n=194,237,38,42) | 6.2 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week52:Not satisfied/dissatisfied(n=194,237,38,42) | 1.5 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly dissatisfied(n=194,237,38,42) | 1.5 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat dissatisfied(n=194,237,38,42) | 2.6 percentage of Participants |
| CP-690,550 5mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very dissatisfied(n=194,237,38,42) | 1.0 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week52:Not satisfied/dissatisfied(n=194,237,38,42) | 1.3 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very satisfied(n=337,339,74,76) | 60.5 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very satisfied(n=300,320,68,72) | 58.8 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly dissatisfied(n=300,320,68,72) | 2.2 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very dissatisfied(n=337,339,74,76) | 3.2 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat satisfied(n=194,237,38,42) | 27.8 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very satisfied(n=194,237,38,42) | 62.9 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat dissatisfied(n=300,320,68,72) | 2.8 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly satisfied(n=337,339,74,76) | 5.6 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat dissatisfied(n=194,237,38,42) | 0.8 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly satisfied(n=194,237,38,42) | 4.6 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very dissatisfied(n=300,320,68,72) | 1.9 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat satisfied(n=300,320,68,72) | 26.3 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly dissatisfied(n=337,339,74,76) | 1.5 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat dissatisfied(n=337,339,74,76) | 1.5 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very dissatisfied(n=194,237,38,42) | 0.8 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly satisfied(n=300,320,68,72) | 5.6 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week16:Not satisfied/dissatisfied(n=337,339,74,76) | 3.8 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat satisfied(n=337,339,74,76) | 23.9 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly dissatisfied(n=194,237,38,42) | 1.7 percentage of Participants |
| CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week28:Not satisfied/dissatisfied(n=300,320,68,72) | 2.5 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat satisfied(n=337,339,74,76) | 20.3 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat dissatisfied(n=337,339,74,76) | 12.2 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very dissatisfied(n=337,339,74,76) | 21.6 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week52:Not satisfied/dissatisfied(n=194,237,38,42) | 2.6 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very satisfied(n=300,320,68,72) | 45.6 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat satisfied(n=300,320,68,72) | 25.0 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly satisfied(n=300,320,68,72) | 11.8 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week28:Not satisfied/dissatisfied(n=300,320,68,72) | 4.4 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly dissatisfied(n=194,237,38,42) | 0 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly dissatisfied(n=300,320,68,72) | 5.9 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat dissatisfied(n=300,320,68,72) | 2.9 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very dissatisfied(n=194,237,38,42) | 2.6 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very dissatisfied(n=300,320,68,72) | 4.4 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very satisfied(n=194,237,38,42) | 50.0 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat dissatisfied(n=194,237,38,42) | 5.3 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat satisfied(n=194,237,38,42) | 28.9 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very satisfied(n=337,339,74,76) | 10.8 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly satisfied(n=337,339,74,76) | 10.8 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly satisfied(n=194,237,38,42) | 10.5 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week16:Not satisfied/dissatisfied(n=337,339,74,76) | 17.6 percentage of Participants |
| Placebo | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly dissatisfied(n=337,339,74,76) | 6.8 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat satisfied(n=194,237,38,42) | 16.7 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week28:Not satisfied/dissatisfied(n=300,320,68,72) | 4.2 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly satisfied(n=194,237,38,42) | 4.8 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very satisfied(n=337,339,74,76) | 17.1 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Somewhat dissatisfied(n=194,237,38,42) | 0 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly satisfied(n=300,320,68,72) | 9.7 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat satisfied(n=300,320,68,72) | 19.4 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat satisfied(n=337,339,74,76) | 14.5 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week52:Not satisfied/dissatisfied(n=194,237,38,42) | 2.4 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very satisfied(n=300,320,68,72) | 54.2 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Somewhat dissatisfied(n=337,339,74,76) | 15.8 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly satisfied(n=337,339,74,76) | 13.2 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very dissatisfied(n=194,237,38,42) | 2.4 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Very dissatisfied(n=300,320,68,72) | 4.2 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Somewhat dissatisfied(n=300,320,68,72) | 2.8 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Slightly dissatisfied(n=194,237,38,42) | 2.4 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Very dissatisfied(n=337,339,74,76) | 19.7 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 52:Very satisfied(n=194,237,38,42) | 71.4 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 16:Slightly dissatisfied(n=337,339,74,76) | 3.9 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week 28:Slightly dissatisfied(n=300,320,68,72) | 5.6 percentage of Participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Patient Satisfaction With Study Medication (PSSM) Score Response | Week16:Not satisfied/dissatisfied(n=337,339,74,76) | 15.8 percentage of Participants |
Secondary
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues.Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Clear(n=340,345,74,76) | 16.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Severe(n=347,348,74,76) | 3.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Moderate(n=362,366,74,75) | 38.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Almost clear(n=376,374,74,76) | 0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Moderate(n=347,348,74,76) | 19.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Mild(n=347,348,74,76) | 32.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Severe(n=362,366,74,75) | 3.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Moderate(n=213,263,46,55) | 5.2 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Almost clear(n=347,348,74,76) | 33.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Clear(n=347,348,74,76) | 11.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Clear(n=354,356,74,76) | 7.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Mild(n=213,263,46,55) | 18.8 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Severe(n=354,356,74,76) | 3.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Moderate(n=354,356,74,76) | 26.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Almost clear(n=354,356,74,76) | 28.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Severe(n=376,374,74,76) | 17.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Mild(n=354,356,74,76) | 34.7 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Severe(n=194,239,38,42) | 0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Almost clear(n=213,263,46,55) | 40.8 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Clear(n=213,263,46,55) | 34.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Clear(n=370,367,73,76) | 0.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Mild(n=194,239,38,42) | 22.7 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Severe(n=305,328,69,72) | 1.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Moderate(n=305,328,69,72) | 10.8 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Almost clear(n=370,367,73,76) | 5.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Clear(n=376,374,74,76) | 0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Mild(n=305,328,69,72) | 25.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Almost clear(n=305,328,69,72) | 39.7 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Mild(n=370,367,73,76) | 30.5 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Almost clear(n=194,239,38,42) | 35.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Clear(n=305,328,69,72) | 22.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Severe(n=327,338,74,76) | 0.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Moderate(n=370,367,73,76) | 55.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Mild(n=376,374,74,76) | 0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Moderate(n=327,338,74,76) | 15.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Mild(n=327,338,74,76) | 29.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Severe(n=370,367,73,76) | 8.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Moderate(n=194,239,38,42) | 5.7 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Almost clear(n=327,338,74,76) | 35.2 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Clear(n=327,338,74,76) | 19.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Clear(n=362,366,74,75) | 1.7 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Clear(n=194,239,38,42) | 36.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Severe(n=340,345,74,76) | 2.6 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16 : Moderate(n=340,345,74,76) | 19.1 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Almost clear(n=362,366,74,75) | 16.0 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Severe(n=213,263,46,55) | 0.9 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Mild(n=340,345,74,76) | 27.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Almost clear(n=340,345,74,76) | 34.4 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Mild(n=362,366,74,75) | 40.3 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Moderate(n=376,374,74,76) | 82.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Almost clear(n=370,367,73,76) | 9.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Clear(n=376,374,74,76) | 0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Almost clear(n=376,374,74,76) | 0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Mild(n=376,374,74,76) | 0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Moderate(n=376,374,74,76) | 81.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Severe(n=376,374,74,76) | 18.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Clear(n=370,367,73,76) | 0.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Mild(n=370,367,73,76) | 31.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Moderate(n=370,367,73,76) | 51.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Severe(n=370,367,73,76) | 7.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Clear(n=362,366,74,75) | 2.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Almost clear(n=362,366,74,75) | 26.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Mild(n=362,366,74,75) | 39.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Moderate(n=362,366,74,75) | 29.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Severe(n=362,366,74,75) | 3.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Clear(n=354,356,74,76) | 10.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Almost clear(n=354,356,74,76) | 41.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Mild(n=354,356,74,76) | 30.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Moderate(n=354,356,74,76) | 16.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Severe(n=354,356,74,76) | 1.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Clear(n=347,348,74,76) | 20.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Almost clear(n=347,348,74,76) | 39.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Mild(n=347,348,74,76) | 26.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Moderate(n=347,348,74,76) | 12.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Severe(n=347,348,74,76) | 1.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Clear(n=340,345,74,76) | 27.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Almost clear(n=340,345,74,76) | 37.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Mild(n=340,345,74,76) | 24.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16 : Moderate(n=340,345,74,76) | 9.6 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Severe(n=340,345,74,76) | 2.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Clear(n=327,338,74,76) | 30.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Almost clear(n=327,338,74,76) | 35.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Mild(n=327,338,74,76) | 24.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Moderate(n=327,338,74,76) | 9.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Severe(n=327,338,74,76) | 0.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Clear(n=305,328,69,72) | 30.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Almost clear(n=305,328,69,72) | 39.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Mild(n=305,328,69,72) | 19.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Moderate(n=305,328,69,72) | 7.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Severe(n=305,328,69,72) | 2.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Clear(n=213,263,46,55) | 35.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Almost clear(n=213,263,46,55) | 44.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Mild(n=213,263,46,55) | 13.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Moderate(n=213,263,46,55) | 5.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Severe(n=213,263,46,55) | 1.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Clear(n=194,239,38,42) | 39.3 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Almost clear(n=194,239,38,42) | 38.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Mild(n=194,239,38,42) | 15.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Moderate(n=194,239,38,42) | 5.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Severe(n=194,239,38,42) | 0.4 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Mild(n=362,366,74,75) | 17.6 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Clear(n=340,345,74,76) | 6.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Almost clear(n=340,345,74,76) | 10.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Almost clear(n=362,366,74,75) | 6.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Moderate(n=194,239,38,42) | 7.9 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Mild(n=340,345,74,76) | 25.7 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Severe(n=213,263,46,55) | 2.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16 : Moderate(n=340,345,74,76) | 50.0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Clear(n=362,366,74,75) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Severe(n=340,345,74,76) | 6.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Mild(n=376,374,74,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Clear(n=327,338,74,76) | 10.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Severe(n=370,367,73,76) | 15.1 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Almost clear(n=327,338,74,76) | 23.0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Clear(n=194,239,38,42) | 34.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Mild(n=327,338,74,76) | 41.9 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Moderate(n=370,367,73,76) | 74.0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Moderate(n=327,338,74,76) | 24.3 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Severe(n=327,338,74,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Mild(n=370,367,73,76) | 8.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Clear(n=376,374,74,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Clear(n=305,328,69,72) | 20.3 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Almost clear(n=194,239,38,42) | 36.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Almost clear(n=305,328,69,72) | 36.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Almost clear(n=370,367,73,76) | 2.7 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Mild(n=305,328,69,72) | 23.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Almost clear(n=376,374,74,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Moderate(n=305,328,69,72) | 20.3 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Clear(n=370,367,73,76) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Severe(n=305,328,69,72) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Mild(n=194,239,38,42) | 21.1 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Clear(n=213,263,46,55) | 32.6 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Severe(n=376,374,74,76) | 12.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Almost clear(n=213,263,46,55) | 37.0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Almost clear(n=354,356,74,76) | 9.5 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Mild(n=354,356,74,76) | 27.0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Moderate(n=354,356,74,76) | 51.4 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Clear(n=354,356,74,76) | 2.7 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Severe(n=354,356,74,76) | 9.5 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Mild(n=213,263,46,55) | 21.7 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Clear(n=347,348,74,76) | 5.4 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Severe(n=362,366,74,75) | 9.5 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Almost clear(n=347,348,74,76) | 9.5 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Moderate(n=376,374,74,76) | 87.8 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Mild(n=347,348,74,76) | 29.7 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Moderate(n=362,366,74,75) | 66.2 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Severe(n=194,239,38,42) | 0 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Moderate(n=347,348,74,76) | 47.3 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Moderate(n=213,263,46,55) | 6.5 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Severe(n=347,348,74,76) | 8.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Moderate(n=354,356,74,76) | 52.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Moderate(n=213,263,46,55) | 1.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Mild(n=305,328,69,72) | 18.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Clear(n=340,345,74,76) | 2.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Almost clear(n=362,366,74,75) | 5.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Mild(n=376,374,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Clear(n=370,367,73,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Almost clear(n=340,345,74,76) | 6.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Almost clear(n=347,348,74,76) | 5.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Clear(n=376,374,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Moderate(n=305,328,69,72) | 9.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Mild(n=340,345,74,76) | 38.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Clear(n=362,366,74,75) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Moderate(n=362,366,74,75) | 61.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Severe(n=194,239,38,42) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16 : Moderate(n=340,345,74,76) | 47.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Severe(n=354,356,74,76) | 6.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Severe(n=213,263,46,55) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Severe(n=305,328,69,72) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 16: Severe(n=340,345,74,76) | 5.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Severe(n=370,367,73,76) | 9.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Severe(n=376,374,74,76) | 15.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Severe(n=362,366,74,75) | 5.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Clear(n=327,338,74,76) | 5.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 4: Mild(n=362,366,74,75) | 28.0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Moderate(n=194,239,38,42) | 4.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Clear(n=213,263,46,55) | 38.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Almost clear(n=327,338,74,76) | 35.5 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Moderate(n=370,367,73,76) | 71.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Severe(n=347,348,74,76) | 7.9 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Mild(n=194,239,38,42) | 21.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Mild(n=327,338,74,76) | 40.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Clear(n=347,348,74,76) | 2.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Clear(n=194,239,38,42) | 40.5 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Almost clear(n=354,356,74,76) | 5.3 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Moderate(n=327,338,74,76) | 18.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Mild(n=370,367,73,76) | 15.8 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Almost clear(n=376,374,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Mild(n=347,348,74,76) | 38.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 20: Severe(n=327,338,74,76) | 0 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Almost clear(n=213,263,46,55) | 43.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 40: Mild(n=213,263,46,55) | 16.4 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Mild(n=354,356,74,76) | 32.9 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Clear(n=305,328,69,72) | 30.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 2: Almost clear(n=370,367,73,76) | 3.9 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 8: Clear(n=354,356,74,76) | 2.6 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Baseline: Moderate(n=376,374,74,76) | 84.2 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 28: Almost clear(n=305,328,69,72) | 41.7 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 12: Moderate(n=347,348,74,76) | 46.1 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score | Week 52: Almost clear(n=194,239,38,42) | 33.3 percentage of participants |
Secondary
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
Time frame: Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 28 | 50.53 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 20 | 47.34 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 52 | 36.97 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 12 | 41.49 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 8 | 33.51 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 4 | 17.02 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 40 | 42.55 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 16 | 46.01 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 2 | 5.32 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 16 | 59.09 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 28 | 62.03 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 20 | 59.09 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 4 | 27.81 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 2 | 9.63 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 8 | 49.20 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 52 | 50.00 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 40 | 55.88 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 12 | 55.35 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 16 | 17.57 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 2 | 2.70 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 4 | 6.76 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 8 | 12.16 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 12 | 14.86 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 20 | 33.78 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 28 | 52.70 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 40 | 43.24 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 52 | 36.49 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 28 | 68.42 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 12 | 7.89 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 8 | 7.89 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 52 | 40.79 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 40 | 59.21 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 4 | 5.26 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 20 | 40.79 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 16 | 9.21 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | Week 2 | 3.95 percentage of participants |
Secondary
Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
Time frame: Week 4
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4 | 17.02 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4 | 27.81 percentage of participants |
| Placebo | Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 4 | 5.18 percentage of participants |
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [1.89, 8.95]Cochran-Mantel-Haenszel
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [4.08, 19.95]Cochran-Mantel-Haenszel
p-value: 0.000495% CI: [4.87, 16.71]Normal Approximation
Secondary
Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least a 50% reduction in PASI relative to Baseline. Percentage of participants with PASI 50 response is reported.
Time frame: Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 28 | 68.88 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 20 | 67.55 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 52 | 48.67 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 12 | 61.17 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 8 | 51.60 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 4 | 28.19 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 40 | 53.46 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 16 | 63.30 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 2 | 9.31 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 16 | 74.33 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 28 | 77.27 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 20 | 78.34 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 4 | 41.44 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 2 | 12.30 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 8 | 66.84 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 52 | 62.03 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 40 | 67.65 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 12 | 72.99 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 16 | 29.73 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 2 | 2.70 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 4 | 9.46 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 8 | 18.92 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 12 | 25.68 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 20 | 56.76 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 28 | 70.27 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 40 | 56.76 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 52 | 48.65 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 28 | 76.32 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 12 | 15.79 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 8 | 14.47 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 52 | 52.63 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 40 | 69.74 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 4 | 11.84 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 20 | 63.16 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 16 | 23.68 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 50 (PASI 50) Response | Week 2 | 6.58 percentage of participants |
Secondary
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.
Time frame: Week 4
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4 | 7.45 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4 | 14.17 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 4 | 4.15 percentage of participants |
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: 0.178695% CI: [0.74, 4.62]Cochran-Mantel-Haenszel
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error.Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: 0.000395% CI: [1.77, 10.25]Cochran-Mantel-Haenszel
p-value: 0.002995% CI: [2.3, 11.14]Normal Approximation
Secondary
Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline. Percentage of participants with PASI 90 response is reported.
Time frame: Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. NRI method (participants with missing values considered as non-responders) was used.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 8 | 9.04 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 40 | 28.99 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 16 | 24.47 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 12 | 18.09 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 4 | 2.66 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 28 | 29.52 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 52 | 27.39 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 20 | 29.52 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 2 | 0.27 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 16 | 38.77 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 2 | 0.27 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 4 | 2.67 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 8 | 15.24 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 12 | 29.68 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 20 | 41.98 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 28 | 44.12 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 40 | 40.11 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 52 | 36.36 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 16 | 9.46 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 20 | 14.86 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 52 | 22.97 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 4 | 0.00 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 28 | 31.08 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 40 | 27.03 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 12 | 5.41 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 2 | 0.00 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 8 | 4.05 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 28 | 46.05 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 16 | 3.95 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 40 | 43.42 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 20 | 14.47 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 4 | 0.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 2 | 0.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 52 | 32.89 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 8 | 2.63 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI 90) Response | Week 12 | 3.95 percentage of participants |
Secondary
Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked).
Time frame: Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 2 (n=369,367,73,76) | 0.54 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 12 (n=347,348,74,76) | 1.15 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 16 (n=340,345,74,76) | 1.47 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 20 (n=327,338,74,76) | 0.61 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 40 (n=213,263,46,55) | 0.00 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 4 (n=363,366,74,75) | 0.83 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 28 (n=305,327,69,72) | 0.66 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 52 (n=194,239,38,42) | 0.00 percentage of participants |
| CP-690,550 5mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 8 (n=354,356,74,76) | 1.13 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 16 (n=340,345,74,76) | 1.16 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 4 (n=363,366,74,75) | 1.09 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 12 (n=347,348,74,76) | 1.15 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 20 (n=327,338,74,76) | 0.30 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 28 (n=305,327,69,72) | 0.31 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 52 (n=194,239,38,42) | 0.00 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 2 (n=369,367,73,76) | 1.09 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 8 (n=354,356,74,76) | 0.84 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 40 (n=213,263,46,55) | 0.76 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 2 (n=369,367,73,76) | 1.37 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 40 (n=213,263,46,55) | 2.17 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 52 (n=194,239,38,42) | 0.00 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 16 (n=340,345,74,76) | 10.81 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 4 (n=363,366,74,75) | 2.70 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 20 (n=327,338,74,76) | 4.05 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 8 (n=354,356,74,76) | 4.05 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 12 (n=347,348,74,76) | 8.11 percentage of participants |
| Placebo | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 28 (n=305,327,69,72) | 2.90 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 52 (n=194,239,38,42) | 0.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 16 (n=340,345,74,76) | 9.21 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 2 (n=369,367,73,76) | 1.32 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 20 (n=327,338,74,76) | 1.32 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 4 (n=363,366,74,75) | 4.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 8 (n=354,356,74,76) | 7.89 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 28 (n=305,327,69,72) | 0.00 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 12 (n=347,348,74,76) | 7.89 percentage of participants |
| Placebo, Then CP-690,550 10 mg | Percentage of Participants With Psoriasis Area and Severity Index (PASI) Score of at Least 125% of Baseline PASI Score | Week 40 (n=213,263,46,55) | 0.00 percentage of participants |
Secondary
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis.
Time frame: Baseline, Week 16
Population: FAS included participants who were randomized to study, received at least 1 dose investigational drug. Participants from 1 site were excluded due to GCP compliance issues. 'N' (number of participants analyzed) were participants who were evaluable (had nail psoriasis at Baseline and had at least one measurement during follow up) for this measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 | -21.62 percent change | Standard Error 7.65 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 | -25.97 percent change | Standard Error 7.87 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 | 15.82 percent change | Standard Error 11.27 |
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: 0.006295% CI: [-64.19, -10.68]Mixed Models Analysis
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 response at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: 0.002595% CI: [-68.8, -14.78]Mixed Models Analysis
Comparison: LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.p-value: 0.69295% CI: [-25.91, 17.21]Mixed Models Analysis
Secondary
Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52
The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop \[salmon patch dyschromia\]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 \[absence of psoriasis\] to 4 \[presence of psoriasis in all 4 quadrants\]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores = more severe psoriasis. 'N' (number of participants analyzed) signifies participants with baseline nail psoriasis and who were unique in longitudinal model.
Time frame: Baseline,Week 8,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 8 | -11.95 percent change | Standard Error 6.56 |
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 16 | -21.56 percent change | Standard Error 7.65 |
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 20 | -24.02 percent change | Standard Error 9.5 |
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 28 | -46.40 percent change | Standard Error 6.8 |
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 40 | -54.22 percent change | Standard Error 5.7 |
| CP-690,550 5mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 52 | -56.38 percent change | Standard Error 5.55 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 52 | -65.06 percent change | Standard Error 5.17 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 28 | -53.80 percent change | Standard Error 6.85 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 8 | 0.55 percent change | Standard Error 6.73 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 20 | -35.56 percent change | Standard Error 9.65 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 16 | -25.87 percent change | Standard Error 7.83 |
| CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 40 | -60.39 percent change | Standard Error 5.39 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 16 | -10.70 percent change | Standard Error 17.32 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 20 | -12.19 percent change | Standard Error 21.3 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 28 | -31.97 percent change | Standard Error 15.17 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 52 | -69.87 percent change | Standard Error 12.46 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 40 | -67.71 percent change | Standard Error 12.43 |
| Placebo | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 8 | -14.70 percent change | Standard Error 15.06 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 40 | -51.65 percent change | Standard Error 10.52 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 52 | -72.94 percent change | Standard Error 10.57 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 16 | 31.51 percent change | Standard Error 15.32 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change Week 28 | 5.38 percent change | Standard Error 13.34 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 8 | 11.37 percent change | Standard Error 13.31 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score at Week 8, 16, 20, 28, 40 and 52 | Percent Change at Week 20 | 37.72 percent change | Standard Error 18.83 |
Secondary
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Baseline, Week 2, 4, 8, 12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'N' (number of participants analyzed) signifies the unique participants in the longitudinal model.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -71.71 percent change | Standard Error 1.59 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -67.66 percent change | Standard Error 1.6 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -63.98 percent change | Standard Error 2.1 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -57.96 percent change | Standard Error 1.73 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -50.36 percent change | Standard Error 1.64 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -34.62 percent change | Standard Error 1.44 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -67.88 percent change | Standard Error 1.9 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -62.06 percent change | Standard Error 1.81 |
| CP-690,550 5mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -18.21 percent change | Standard Error 1.1 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -73.21 percent change | Standard Error 1.8 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -79.17 percent change | Standard Error 1.56 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -77.82 percent change | Standard Error 1.59 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -42.21 percent change | Standard Error 1.44 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -22.15 percent change | Standard Error 1.1 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -61.31 percent change | Standard Error 1.64 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -71.82 percent change | Standard Error 2.02 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -75.71 percent change | Standard Error 1.83 |
| CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -69.63 percent change | Standard Error 1.73 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -25.91 percent change | Standard Error 3.97 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -5.07 percent change | Standard Error 2.46 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -14.25 percent change | Standard Error 3.2 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -22.18 percent change | Standard Error 3.64 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -24.39 percent change | Standard Error 3.82 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -51.51 percent change | Standard Error 3.48 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -65.89 percent change | Standard Error 3.4 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -60.94 percent change | Standard Error 4.06 |
| Placebo | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -56.64 percent change | Standard Error 4.54 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -76.28 percent change | Standard Error 3.36 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -19.37 percent change | Standard Error 3.77 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -17.40 percent change | Standard Error 3.59 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -69.52 percent change | Standard Error 4.42 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -72.19 percent change | Standard Error 3.95 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -14.41 percent change | Standard Error 3.17 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -57.68 percent change | Standard Error 3.44 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -22.50 percent change | Standard Error 3.92 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -11.41 percent change | Standard Error 2.42 |
Secondary
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16
Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
Time frame: Baseline, Week 16
Population: FAS included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP non-compliance. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16 | -54.86 percent change | Standard Error 2.12 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16 | -67.22 percent change | Standard Error 2.11 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16 | -9.12 percent change | Standard Error 3.02 |
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error.Sequential order of testing: percent change in BSA at Week 16,PASI90 response at Week 16, change in Dermatology Life Quality Index(DLQI) total score at Week 16,PGA response at Week 4,PASI75 at Week 4, change in DLQI total score at Week 4, percent change in Nail Psoriasis Severity Index(NAPSI) score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [-52.98, -38.49]Mixed Models Analysis
Comparison: For key secondary endpoint, family-wise step-down procedure was used to control Type I error.Sequential order of testing: percent change in BSA at Week 16,PASI90 response at Week 16, change in Dermatology Life Quality Index(DLQI) total score at Week 16,PGA response at Week 4,PASI75 at Week 4, change in DLQI total score at Week 4, percent change in Nail Psoriasis Severity Index(NAPSI) score at Week 16. If comparison at preceding step was significant, then subsequent comparisons were significant.p-value: <0.000195% CI: [-65.33, -50.86]Mixed Models Analysis
Comparison: LS mean difference was derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value and repeated measures for visit. Unstructured covariance matrix was used.p-value: <0.000195% CI: [-18.24, -6.48]Mixed Models Analysis
Secondary
Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52
Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'N'(number of participants analyzed) signifies the unique participants in the longitudinal model.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -68.41 percent change | Standard Error 1.84 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -61.63 percent change | Standard Error 1.98 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -71.23 percent change | Standard Error 1.86 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -47.94 percent change | Standard Error 1.98 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -36.67 percent change | Standard Error 1.86 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -18.73 percent change | Standard Error 1.44 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -69.93 percent change | Standard Error 1.86 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -54.90 percent change | Standard Error 2.08 |
| CP-690,550 5mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -7.62 percent change | Standard Error 0.91 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -67.16 percent change | Standard Error 2.07 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -77.92 percent change | Standard Error 1.81 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -74.17 percent change | Standard Error 1.97 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -23.68 percent change | Standard Error 1.44 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -7.80 percent change | Standard Error 0.91 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -46.76 percent change | Standard Error 1.86 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -77.20 percent change | Standard Error 1.76 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -77.78 percent change | Standard Error 1.79 |
| CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -60.67 percent change | Standard Error 1.98 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -18.31 percent change | Standard Error 4.56 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | 1.77 percent change | Standard Error 2.04 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -2.52 percent change | Standard Error 3.21 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -10.57 percent change | Standard Error 4.12 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -15.27 percent change | Standard Error 4.37 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -37.33 percent change | Standard Error 4.3 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -57.91 percent change | Standard Error 3.94 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -61.08 percent change | Standard Error 3.98 |
| Placebo | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -63.88 percent change | Standard Error 4.03 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 28 | -67.84 percent change | Standard Error 3.88 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 12 | -7.55 percent change | Standard Error 4.32 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 8 | -4.57 percent change | Standard Error 4.07 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 52 | -76.60 percent change | Standard Error 3.88 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 40 | -70.79 percent change | Standard Error 3.86 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 4 | -1.70 percent change | Standard Error 3.18 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 20 | -38.93 percent change | Standard Error 4.24 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 16 | -8.13 percent change | Standard Error 4.5 |
| Placebo, Then CP-690,550 10 mg | Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 2, 4, 8, 12, 16, 20, 28, 40 and 52 | Change at Week 2 | -1.13 percent change | Standard Error 2 |
Secondary
Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among participants achieving PGA response at Week 16 is reported. Percent probability and 95% confidence interval (CI) were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).
Time frame: Week 52
Population: FAS participants who had PGA response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52 | 63.55 percent probability of response |
| CP-690,550 10 mg | Percent Probability of Participants Maintaining Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 52 | 71.71 percent probability of response |
Secondary
Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52
The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response = at least 75% reduction in PASI relative to Baseline. Maintenance of PASI 75 response at Week 52 among participants achieving PASI 75 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).
Time frame: Week 52
Population: FAS participants who had PASI 75 response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52 | 74.38 percent probability of response |
| CP-690,550 10 mg | Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 52 | 78.99 percent probability of response |
Secondary
Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52
The PASI quantifies severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response = at least 90% reduction in PASI relative to Baseline. Maintenance of PASI 90 response at Week 52 among participants achieving PASI 90 response at Week 16 is reported. Percent probability and 95% CI were estimated based on the product limit estimator in survival analyses. Event is loss of response. Probability of maintaining response is (1-probability of loss of response).
Time frame: Week 52
Population: FAS participants who had PASI 90 response at Week 16. Data was not analyzed for participants initially randomized to placebo arm as they were re-randomized to active treatment group at Week 16 and thus maintaining response at Week 52 was not relevant. 'N' (number of participants analyzed) = participants with non-missing post-baseline response data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 5mg | Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52 | 70.33 percent probability of response |
| CP-690,550 10 mg | Percent Probability of Participants Maintaining Psoriasis Area and Severity Index 90 (PASI 90) Response at Week 52 | 63.83 percent probability of response |
Secondary
Psoriasis Area and Severity Index (PASI) Component Scores
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4 and where higher scores indicate greater severity of psoriatic lesions.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues.Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Trunk)(n=363,366,74,75) | 1.72 units on a scale | Standard Deviation 0.99 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Upper limbs)(n=376,374,74,76) | 2.90 units on a scale | Standard Deviation 0.61 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Trunk)(n=376,374,74,76) | 2.93 units on a scale | Standard Deviation 0.7 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Lower limbs)(n=376,374,74,76) | 3.18 units on a scale | Standard Deviation 0.6 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Head\Neck)(n=376,374,74,76) | 2.02 units on a scale | Standard Deviation 1.03 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Upper limbs)(n=376,374,74,76) | 2.74 units on a scale | Standard Deviation 0.7 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Trunk)(n=376,374,74,76) | 2.72 units on a scale | Standard Deviation 0.77 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Lower limbs)(n=376,374,74,76) | 2.99 units on a scale | Standard Deviation 0.7 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Head\Neck)(n=376,374,74,76) | 2.32 units on a scale | Standard Deviation 1.1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Upper limbs)(n=376,374,74,76) | 2.77 units on a scale | Standard Deviation 0.73 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Trunk)(n=376,374,74,76) | 2.68 units on a scale | Standard Deviation 0.77 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Lower limbs)(n=376,374,74,76) | 3.04 units on a scale | Standard Deviation 0.66 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | 1.76 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | 2.27 units on a scale | Standard Deviation 0.82 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Trunk)(n=369,367,73,76) | 2.35 units on a scale | Standard Deviation 0.89 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | 2.63 units on a scale | Standard Deviation 0.83 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Head\Neck)(n=369,367,73,76) | 1.53 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Upper limbs)(n=369,367,73,76) | 2.20 units on a scale | Standard Deviation 0.85 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Trunk)(n=369,367,73,76) | 2.22 units on a scale | Standard Deviation 0.91 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Lower limbs)(n=369,367,73,76) | 2.48 units on a scale | Standard Deviation 0.83 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | 1.69 units on a scale | Standard Deviation 1.15 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | 2.16 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Trunk)(n=369,367,73,76) | 2.12 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | 2.48 units on a scale | Standard Deviation 0.9 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | 1.31 units on a scale | Standard Deviation 1.09 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | 1.82 units on a scale | Standard Deviation 0.89 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Trunk)(n=363,366,74,75) | 1.89 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | 2.11 units on a scale | Standard Deviation 0.9 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Head\Neck)(n=363,366,74,75) | 1.08 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Upper limbs)(n=363,366,74,75) | 1.67 units on a scale | Standard Deviation 0.91 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Head\Neck)(n=376,374,74,76) | 2.30 units on a scale | Standard Deviation 1.04 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Lower limbs)(n=363,366,74,75) | 1.93 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | 1.20 units on a scale | Standard Deviation 1.11 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | 1.64 units on a scale | Standard Deviation 0.97 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Trunk)(n=363,366,74,75) | 1.61 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | 1.95 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | 0.96 units on a scale | Standard Deviation 1.02 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | 1.40 units on a scale | Standard Deviation 0.91 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Trunk)(n=354,356,74,76) | 1.37 units on a scale | Standard Deviation 1.02 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | 1.60 units on a scale | Standard Deviation 0.99 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Head\Neck)(n=354,356,74,76) | 0.78 units on a scale | Standard Deviation 0.94 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Upper limbs)(n=354,356,74,76) | 1.29 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Trunk)(n=354,356,74,76) | 1.21 units on a scale | Standard Deviation 1.03 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Lower limbs)(n=354,356,74,76) | 1.40 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | 0.89 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | 1.29 units on a scale | Standard Deviation 1.01 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Trunk)(n=354,356,74,76) | 1.11 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | 1.36 units on a scale | Standard Deviation 1.08 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | 0.78 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | 1.19 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Trunk)(n=347,348,74,76) | 1.11 units on a scale | Standard Deviation 1.03 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | 1.32 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Head\Neck)(n=347,348,74,76) | 0.63 units on a scale | Standard Deviation 0.9 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Upper limbs)(n=347,348,74,76) | 1.13 units on a scale | Standard Deviation 0.99 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Trunk)(n=347,348,74,76) | 0.96 units on a scale | Standard Deviation 1.02 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Lower limbs)(n=347,348,74,76) | 1.12 units on a scale | Standard Deviation 1.04 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | 0.74 units on a scale | Standard Deviation 1.01 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | 1.11 units on a scale | Standard Deviation 1.01 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Trunk)(n=347,348,74,76) | 0.88 units on a scale | Standard Deviation 1.01 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | 1.07 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | 0.74 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | 1.08 units on a scale | Standard Deviation 0.97 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Trunk)(n=340,345,74,76) | 0.94 units on a scale | Standard Deviation 1.06 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | 1.17 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Head\Neck)(n=340,345,74,76) | 0.58 units on a scale | Standard Deviation 0.86 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Upper limbs)(n=340,345,74,76) | 1.05 units on a scale | Standard Deviation 1.02 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Trunk)(n=340,345,74,76) | 0.79 units on a scale | Standard Deviation 1.02 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Lower limbs)(n=340,345,74,76) | 1.01 units on a scale | Standard Deviation 1.06 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | 0.68 units on a scale | Standard Deviation 0.99 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | 1.03 units on a scale | Standard Deviation 1.06 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Trunk)(n=340,345,74,76) | 0.75 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | 1.00 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | 0.68 units on a scale | Standard Deviation 0.91 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | 0.98 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Trunk)(n=327,338,74,76) | 0.81 units on a scale | Standard Deviation 0.99 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | 1.02 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Head\Neck)(n=327,338,74,76) | 0.48 units on a scale | Standard Deviation 0.76 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Upper limbs)(n=327,338,74,76) | 0.96 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Trunk)(n=327,338,74,76) | 0.71 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Lower limbs)(n=327,338,74,76) | 0.87 units on a scale | Standard Deviation 1 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | 0.63 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | 1.00 units on a scale | Standard Deviation 1.05 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Trunk)(n=327,338,74,76) | 0.66 units on a scale | Standard Deviation 0.93 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | 0.89 units on a scale | Standard Deviation 1.08 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | 0.65 units on a scale | Standard Deviation 0.93 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | 0.96 units on a scale | Standard Deviation 0.98 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Trunk)(n=305,327,69,72) | 0.81 units on a scale | Standard Deviation 1.06 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | 0.96 units on a scale | Standard Deviation 1.11 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Head\Neck)(n=305,327,69,72) | 0.47 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Upper limbs)(n=305,327,69,72) | 0.95 units on a scale | Standard Deviation 1.02 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Trunk)(n=305,327,69,72) | 0.67 units on a scale | Standard Deviation 0.94 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Lower limbs)(n=305,327,69,72) | 0.80 units on a scale | Standard Deviation 1.04 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | 0.60 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | 0.96 units on a scale | Standard Deviation 1.08 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Trunk)(n=305,327,69,72) | 0.63 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | 0.84 units on a scale | Standard Deviation 1.11 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | 0.48 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | 0.76 units on a scale | Standard Deviation 0.85 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Trunk)(n=213,263,46,55) | 0.62 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | 0.72 units on a scale | Standard Deviation 0.94 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Head\Neck)(n=213,263,46,55) | 0.36 units on a scale | Standard Deviation 0.64 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Upper limbs)(n=213,263,46,55) | 0.73 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Trunk)(n=213,263,46,55) | 0.51 units on a scale | Standard Deviation 0.89 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Lower limbs)(n=213,263,46,55) | 0.62 units on a scale | Standard Deviation 0.91 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | 0.46 units on a scale | Standard Deviation 0.81 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | 0.74 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Trunk)(n=213,263,46,55) | 0.47 units on a scale | Standard Deviation 0.84 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | 0.63 units on a scale | Standard Deviation 0.96 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | 0.48 units on a scale | Standard Deviation 0.77 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | 0.77 units on a scale | Standard Deviation 0.88 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Trunk)(n=194,239,38,42) | 0.60 units on a scale | Standard Deviation 0.91 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | 0.76 units on a scale | Standard Deviation 0.97 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Head\Neck)(n=194,239,38,42) | 0.33 units on a scale | Standard Deviation 0.6 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Upper limbs)(n=194,239,38,42) | 0.69 units on a scale | Standard Deviation 0.87 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Trunk)(n=194,239,38,42) | 0.46 units on a scale | Standard Deviation 0.74 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Lower limbs)(n=194,239,38,42) | 0.64 units on a scale | Standard Deviation 0.89 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | 0.45 units on a scale | Standard Deviation 0.78 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | 0.70 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Trunk)(n=194,239,38,42) | 0.45 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | 0.64 units on a scale | Standard Deviation 0.92 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | 0.63 units on a scale | Standard Deviation 0.87 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | 1.06 units on a scale | Standard Deviation 1.08 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Lower limbs)(n=369,367,73,76) | 2.60 units on a scale | Standard Deviation 0.81 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Head\Neck)(n=194,239,38,42) | 0.49 units on a scale | Standard Deviation 0.76 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | 0.84 units on a scale | Standard Deviation 1.03 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | 1.37 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Head\Neck)(n=354,356,74,76) | 1.05 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Head\Neck)(n=305,327,69,72) | 0.71 units on a scale | Standard Deviation 0.9 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Lower limbs)(n=363,366,74,75) | 2.16 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Trunk)(n=340,345,74,76) | 1.34 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Trunk)(n=369,367,73,76) | 2.33 units on a scale | Standard Deviation 0.87 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | 1.20 units on a scale | Standard Deviation 1.02 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Trunk)(n=305,327,69,72) | 1.00 units on a scale | Standard Deviation 1.07 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | 1.51 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Head\Neck)(n=213,263,46,55) | 0.48 units on a scale | Standard Deviation 0.76 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | 1.17 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Upper limbs)(n=354,356,74,76) | 1.59 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Head\Neck)(n=340,345,74,76) | 0.89 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | 2.34 units on a scale | Standard Deviation 0.9 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | 0.87 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Trunk)(n=213,263,46,55) | 0.56 units on a scale | Standard Deviation 0.91 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Upper limbs)(n=340,345,74,76) | 1.28 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Upper limbs)(n=369,367,73,76) | 2.36 units on a scale | Standard Deviation 0.82 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | 0.88 units on a scale | Standard Deviation 0.95 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Trunk)(n=363,366,74,75) | 1.89 units on a scale | Standard Deviation 0.94 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Trunk)(n=340,345,74,76) | 1.16 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Trunk)(n=354,356,74,76) | 1.54 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | 1.17 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Trunk)(n=327,338,74,76) | 0.89 units on a scale | Standard Deviation 1.06 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Lower limbs)(n=340,345,74,76) | 1.34 units on a scale | Standard Deviation 1.14 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Trunk)(n=363,366,74,75) | 1.83 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | 1.14 units on a scale | Standard Deviation 1.07 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Trunk)(n=194,239,38,42) | 0.74 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | 1.00 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Trunk)(n=305,327,69,72) | 0.81 units on a scale | Standard Deviation 1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | 0.84 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | 0.74 units on a scale | Standard Deviation 0.95 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | 1.31 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Head\Neck)(n=369,367,73,76) | 1.73 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Lower limbs)(n=327,338,74,76) | 1.20 units on a scale | Standard Deviation 1.06 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Lower limbs)(n=354,356,74,76) | 1.71 units on a scale | Standard Deviation 1.03 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Trunk)(n=340,345,74,76) | 1.08 units on a scale | Standard Deviation 1.15 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Head\Neck)(n=363,366,74,75) | 1.30 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Trunk)(n=327,338,74,76) | 0.98 units on a scale | Standard Deviation 1.08 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Upper limbs)(n=327,338,74,76) | 1.14 units on a scale | Standard Deviation 1.06 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | 1.38 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | 2.78 units on a scale | Standard Deviation 0.81 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | 0.91 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | 0.72 units on a scale | Standard Deviation 0.95 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | 0.93 units on a scale | Standard Deviation 1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Lower limbs)(n=194,239,38,42) | 0.69 units on a scale | Standard Deviation 0.92 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Head\Neck)(n=327,338,74,76) | 0.77 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | 0.70 units on a scale | Standard Deviation 0.9 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | 1.23 units on a scale | Standard Deviation 1.01 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | 1.13 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | 0.84 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Trunk)(n=363,366,74,75) | 2.07 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Trunk)(n=327,338,74,76) | 1.14 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Trunk)(n=369,367,73,76) | 2.45 units on a scale | Standard Deviation 0.85 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | 1.34 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Upper limbs)(n=213,263,46,55) | 0.78 units on a scale | Standard Deviation 0.91 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | 1.53 units on a scale | Standard Deviation 1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | 2.00 units on a scale | Standard Deviation 0.86 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | 2.41 units on a scale | Standard Deviation 0.82 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | 2.13 units on a scale | Standard Deviation 1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Trunk)(n=354,356,74,76) | 1.42 units on a scale | Standard Deviation 1.07 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Upper limbs)(n=363,366,74,75) | 1.91 units on a scale | Standard Deviation 0.86 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | 1.07 units on a scale | Standard Deviation 1.07 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | 1.86 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | 1.68 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | 0.67 units on a scale | Standard Deviation 0.85 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Upper limbs)(n=194,239,38,42) | 0.79 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | 1.49 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | 1.10 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | 1.24 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Lower limbs)(n=376,374,74,76) | 3.02 units on a scale | Standard Deviation 0.74 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Trunk)(n=213,263,46,55) | 0.52 units on a scale | Standard Deviation 0.82 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | 1.49 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | 1.42 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Trunk)(n=376,374,74,76) | 2.69 units on a scale | Standard Deviation 0.77 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | 2.53 units on a scale | Standard Deviation 0.91 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Trunk)(n=347,348,74,76) | 1.52 units on a scale | Standard Deviation 1.13 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | 0.82 units on a scale | Standard Deviation 0.93 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Upper limbs)(n=376,374,74,76) | 2.77 units on a scale | Standard Deviation 0.73 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | 0.81 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | 1.72 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | 1.70 units on a scale | Standard Deviation 0.92 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Head\Neck)(n=376,374,74,76) | 2.33 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Trunk)(n=194,239,38,42) | 0.58 units on a scale | Standard Deviation 0.88 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Head\Neck)(n=347,348,74,76) | 0.93 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | 0.85 units on a scale | Standard Deviation 0.87 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Lower limbs)(n=376,374,74,76) | 2.95 units on a scale | Standard Deviation 0.69 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Lower limbs)(n=213,263,46,55) | 0.70 units on a scale | Standard Deviation 0.89 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Upper limbs)(n=347,348,74,76) | 1.37 units on a scale | Standard Deviation 1.02 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Trunk)(n=369,367,73,76) | 2.18 units on a scale | Standard Deviation 0.92 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Trunk)(n=376,374,74,76) | 2.69 units on a scale | Standard Deviation 0.76 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Trunk)(n=194,239,38,42) | 0.55 units on a scale | Standard Deviation 0.85 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Trunk)(n=347,348,74,76) | 1.30 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Trunk)(n=354,356,74,76) | 1.75 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Upper limbs)(n=376,374,74,76) | 2.79 units on a scale | Standard Deviation 0.69 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Lower limbs)(n=305,327,69,72) | 1.08 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Lower limbs)(n=347,348,74,76) | 1.50 units on a scale | Standard Deviation 1.11 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Trunk)(n=213,263,46,55) | 0.65 units on a scale | Standard Deviation 0.88 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Head\Neck)(n=376,374,74,76) | 2.11 units on a scale | Standard Deviation 1.05 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Lower limbs)(n=376,374,74,76) | 3.18 units on a scale | Standard Deviation 0.63 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | 0.99 units on a scale | Standard Deviation 1.1 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | 2.25 units on a scale | Standard Deviation 0.92 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Trunk)(n=376,374,74,76) | 2.92 units on a scale | Standard Deviation 0.7 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | 0.67 units on a scale | Standard Deviation 0.95 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | 1.38 units on a scale | Standard Deviation 1.09 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | 1.05 units on a scale | Standard Deviation 1.07 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Upper limbs)(n=376,374,74,76) | 2.89 units on a scale | Standard Deviation 0.66 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | 1.92 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Trunk)(n=347,348,74,76) | 1.22 units on a scale | Standard Deviation 1.12 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | 1.85 units on a scale | Standard Deviation 0.92 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Trunk)(n=305,327,69,72) | 0.90 units on a scale | Standard Deviation 1.04 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Head\Neck)(n=376,374,74,76) | 2.35 units on a scale | Standard Deviation 0.97 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | 1.50 units on a scale | Standard Deviation 1.16 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | 1.80 units on a scale | Standard Deviation 1.19 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Upper limbs)(n=305,327,69,72) | 1.10 units on a scale | Standard Deviation 1.05 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Head\Neck)(n=347,348,74,76) | 1.61 units on a scale | Standard Deviation 1.04 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Trunk)(n=363,366,74,75) | 2.27 units on a scale | Standard Deviation 0.91 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Lower limbs)(n=363,366,74,75) | 2.55 units on a scale | Standard Deviation 0.8 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Trunk)(n=194,239,38,42) | 0.61 units on a scale | Standard Deviation 0.82 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | 2.00 units on a scale | Standard Deviation 1.07 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | 2.31 units on a scale | Standard Deviation 0.94 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Trunk)(n=213,263,46,55) | 0.72 units on a scale | Standard Deviation 0.98 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Trunk)(n=363,366,74,75) | 2.23 units on a scale | Standard Deviation 1.08 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | 2.57 units on a scale | Standard Deviation 0.88 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | 1.85 units on a scale | Standard Deviation 1.02 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | 2.28 units on a scale | Standard Deviation 0.82 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | 1.00 units on a scale | Standard Deviation 1.03 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Trunk)(n=354,356,74,76) | 2.27 units on a scale | Standard Deviation 0.96 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | 2.55 units on a scale | Standard Deviation 0.88 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Head\Neck)(n=354,356,74,76) | 1.62 units on a scale | Standard Deviation 1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Upper limbs)(n=354,356,74,76) | 2.14 units on a scale | Standard Deviation 0.85 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Head\Neck)(n=213,263,46,55) | 0.54 units on a scale | Standard Deviation 0.91 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Trunk)(n=354,356,74,76) | 2.09 units on a scale | Standard Deviation 0.97 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Lower limbs)(n=354,356,74,76) | 2.42 units on a scale | Standard Deviation 0.92 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | 1.82 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | 2.18 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Upper limbs)(n=213,263,46,55) | 0.89 units on a scale | Standard Deviation 1.04 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Trunk)(n=354,356,74,76) | 2.03 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | 2.34 units on a scale | Standard Deviation 0.98 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Lower limbs)(n=194,239,38,42) | 0.76 units on a scale | Standard Deviation 0.97 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | 1.86 units on a scale | Standard Deviation 1.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | 2.18 units on a scale | Standard Deviation 0.88 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Trunk)(n=213,263,46,55) | 0.57 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Trunk)(n=347,348,74,76) | 2.24 units on a scale | Standard Deviation 1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | 2.50 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | 0.98 units on a scale | Standard Deviation 1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Upper limbs)(n=347,348,74,76) | 2.09 units on a scale | Standard Deviation 0.94 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Lower limbs)(n=213,263,46,55) | 0.85 units on a scale | Standard Deviation 0.99 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Trunk)(n=347,348,74,76) | 2.11 units on a scale | Standard Deviation 1.08 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Lower limbs)(n=347,348,74,76) | 2.36 units on a scale | Standard Deviation 0.97 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | 1.77 units on a scale | Standard Deviation 1.1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | 2.04 units on a scale | Standard Deviation 1.01 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | 0.67 units on a scale | Standard Deviation 1.01 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Trunk)(n=347,348,74,76) | 1.97 units on a scale | Standard Deviation 1.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | 2.30 units on a scale | Standard Deviation 1.03 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | 1.91 units on a scale | Standard Deviation 1.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | 2.09 units on a scale | Standard Deviation 1.02 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | 0.89 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Trunk)(n=340,345,74,76) | 2.08 units on a scale | Standard Deviation 1.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | 2.42 units on a scale | Standard Deviation 1.05 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | 0.58 units on a scale | Standard Deviation 0.83 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Head\Neck)(n=340,345,74,76) | 1.66 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Upper limbs)(n=340,345,74,76) | 2.07 units on a scale | Standard Deviation 1.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Trunk)(n=213,263,46,55) | 0.57 units on a scale | Standard Deviation 0.98 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Trunk)(n=340,345,74,76) | 2.01 units on a scale | Standard Deviation 1.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Lower limbs)(n=340,345,74,76) | 2.31 units on a scale | Standard Deviation 1.03 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | 1.74 units on a scale | Standard Deviation 1.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | 2.04 units on a scale | Standard Deviation 1.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | 0.93 units on a scale | Standard Deviation 1.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Trunk)(n=340,345,74,76) | 1.84 units on a scale | Standard Deviation 1.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | 2.16 units on a scale | Standard Deviation 1.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | 1.34 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | 1.59 units on a scale | Standard Deviation 0.96 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | 0.68 units on a scale | Standard Deviation 0.96 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Trunk)(n=327,338,74,76) | 1.59 units on a scale | Standard Deviation 1.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | 1.82 units on a scale | Standard Deviation 1.16 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Head\Neck)(n=327,338,74,76) | 1.11 units on a scale | Standard Deviation 0.92 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Upper limbs)(n=327,338,74,76) | 1.43 units on a scale | Standard Deviation 0.92 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | 1.05 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Trunk)(n=327,338,74,76) | 1.41 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Lower limbs)(n=327,338,74,76) | 1.68 units on a scale | Standard Deviation 0.99 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | 0.95 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | 1.11 units on a scale | Standard Deviation 0.99 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | 1.41 units on a scale | Standard Deviation 1.05 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Trunk)(n=194,239,38,42) | 0.76 units on a scale | Standard Deviation 0.88 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Trunk)(n=327,338,74,76) | 1.31 units on a scale | Standard Deviation 1.08 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | 1.43 units on a scale | Standard Deviation 0.99 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | 0.90 units on a scale | Standard Deviation 1.06 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | 1.26 units on a scale | Standard Deviation 1.01 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | 0.84 units on a scale | Standard Deviation 1.03 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Trunk)(n=305,327,69,72) | 1.09 units on a scale | Standard Deviation 1.2 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | 1.39 units on a scale | Standard Deviation 1.05 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | 0.89 units on a scale | Standard Deviation 1.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Head\Neck)(n=305,327,69,72) | 0.78 units on a scale | Standard Deviation 0.97 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Upper limbs)(n=305,327,69,72) | 1.10 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Head\Neck)(n=194,239,38,42) | 0.53 units on a scale | Standard Deviation 0.8 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Head\Neck)(n=376,374,74,76) | 2.36 units on a scale | Standard Deviation 0.92 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Upper limbs)(n=376,374,74,76) | 2.82 units on a scale | Standard Deviation 0.65 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Trunk)(n=305,327,69,72) | 0.94 units on a scale | Standard Deviation 1.08 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Trunk)(n=376,374,74,76) | 2.96 units on a scale | Standard Deviation 0.71 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Lower limbs)(n=376,374,74,76) | 3.16 units on a scale | Standard Deviation 0.5 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Head\Neck)(n=376,374,74,76) | 2.24 units on a scale | Standard Deviation 0.9 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Upper limbs)(n=376,374,74,76) | 2.66 units on a scale | Standard Deviation 0.63 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Lower limbs)(n=305,327,69,72) | 1.29 units on a scale | Standard Deviation 1.03 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Trunk)(n=376,374,74,76) | 2.69 units on a scale | Standard Deviation 0.68 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Lower limbs)(n=376,374,74,76) | 2.86 units on a scale | Standard Deviation 0.63 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Head\Neck)(n=376,374,74,76) | 2.47 units on a scale | Standard Deviation 1.05 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Upper limbs)(n=376,374,74,76) | 2.78 units on a scale | Standard Deviation 0.73 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | 0.80 units on a scale | Standard Deviation 1.02 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Trunk)(n=376,374,74,76) | 2.77 units on a scale | Standard Deviation 0.79 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Lower limbs)(n=376,374,74,76) | 3.03 units on a scale | Standard Deviation 0.62 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | 2.30 units on a scale | Standard Deviation 0.89 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | 2.70 units on a scale | Standard Deviation 0.74 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | 1.20 units on a scale | Standard Deviation 1.04 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Trunk)(n=369,367,73,76) | 2.82 units on a scale | Standard Deviation 0.73 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | 3.07 units on a scale | Standard Deviation 0.51 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Upper limbs)(n=194,239,38,42) | 0.95 units on a scale | Standard Deviation 0.93 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Head\Neck)(n=369,367,73,76) | 2.11 units on a scale | Standard Deviation 0.86 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Upper limbs)(n=369,367,73,76) | 2.53 units on a scale | Standard Deviation 0.71 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Trunk)(n=305,327,69,72) | 0.96 units on a scale | Standard Deviation 1.17 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Trunk)(n=369,367,73,76) | 2.52 units on a scale | Standard Deviation 0.71 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Lower limbs)(n=369,367,73,76) | 2.73 units on a scale | Standard Deviation 0.71 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | 2.33 units on a scale | Standard Deviation 1.04 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | 2.56 units on a scale | Standard Deviation 0.9 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | 1.22 units on a scale | Standard Deviation 1.04 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Trunk)(n=369,367,73,76) | 2.44 units on a scale | Standard Deviation 0.96 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | 2.71 units on a scale | Standard Deviation 0.84 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Trunk)(n=194,239,38,42) | 0.66 units on a scale | Standard Deviation 0.94 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | 2.11 units on a scale | Standard Deviation 0.9 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | 2.53 units on a scale | Standard Deviation 0.81 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | 0.72 units on a scale | Standard Deviation 1.07 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Trunk)(n=363,366,74,75) | 2.50 units on a scale | Standard Deviation 0.95 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | 2.74 units on a scale | Standard Deviation 0.76 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Head\Neck)(n=363,366,74,75) | 1.86 units on a scale | Standard Deviation 0.91 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Upper limbs)(n=363,366,74,75) | 2.41 units on a scale | Standard Deviation 0.77 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Upper limbs)(n=194,239,38,42) | 0.76 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Head\Neck)(n=213,263,46,55) | 0.58 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Lower limbs)(n=354,356,74,76) | 2.72 units on a scale | Standard Deviation 0.83 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Head\Neck)(n=376,374,74,76) | 2.29 units on a scale | Standard Deviation 0.86 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Trunk)(n=347,348,74,76) | 2.11 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Upper limbs)(n=347,348,74,76) | 2.09 units on a scale | Standard Deviation 0.87 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Trunk)(n=363,366,74,75) | 2.49 units on a scale | Standard Deviation 0.92 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Upper limbs)(n=376,374,74,76) | 2.86 units on a scale | Standard Deviation 0.71 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Head\Neck)(n=369,367,73,76) | 2.11 units on a scale | Standard Deviation 1.03 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Head\Neck)(n=347,348,74,76) | 1.78 units on a scale | Standard Deviation 1.08 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Lower limbs)(n=213,263,46,55) | 0.69 units on a scale | Standard Deviation 0.81 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Trunk)(n=376,374,74,76) | 2.80 units on a scale | Standard Deviation 0.8 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Trunk)(n=305,327,69,72) | 0.76 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Lower limbs)(n=194,239,38,42) | 0.74 units on a scale | Standard Deviation 0.99 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Trunk)(n=354,356,74,76) | 2.46 units on a scale | Standard Deviation 0.97 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Erythema(Lower limbs)(n=376,374,74,76) | 3.17 units on a scale | Standard Deviation 0.64 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Head\Neck)(n=194,239,38,42) | 0.33 units on a scale | Standard Deviation 0.65 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Lower limbs)(n=347,348,74,76) | 2.42 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Head\Neck)(n=213,263,46,55) | 0.51 units on a scale | Standard Deviation 0.72 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Head\Neck)(n=376,374,74,76) | 2.00 units on a scale | Standard Deviation 0.95 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Lower limbs)(n=213,263,46,55) | 0.62 units on a scale | Standard Deviation 0.8 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Trunk)(n=347,348,74,76) | 2.21 units on a scale | Standard Deviation 0.93 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Upper limbs)(n=369,367,73,76) | 2.36 units on a scale | Standard Deviation 0.8 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Upper limbs)(n=376,374,74,76) | 2.86 units on a scale | Standard Deviation 0.74 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Upper limbs)(n=363,366,74,75) | 2.25 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Upper limbs)(n=347,348,74,76) | 2.21 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Upper limbs)(n=354,356,74,76) | 2.47 units on a scale | Standard Deviation 0.93 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Trunk)(n=376,374,74,76) | 2.64 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Lower limbs)(n=305,327,69,72) | 0.89 units on a scale | Standard Deviation 1.08 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Induration(Head\Neck)(n=347,348,74,76) | 1.66 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Trunk)(n=363,366,74,75) | 2.36 units on a scale | Standard Deviation 0.9 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Induration(Lower limbs)(n=376,374,74,76) | 2.92 units on a scale | Standard Deviation 0.74 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Lower limbs)(n=194,239,38,42) | 0.69 units on a scale | Standard Deviation 1 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Lower limbs)(n=347,348,74,76) | 2.61 units on a scale | Standard Deviation 1.05 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Trunk)(n=369,367,73,76) | 2.29 units on a scale | Standard Deviation 0.86 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Head\Neck)(n=376,374,74,76) | 2.30 units on a scale | Standard Deviation 1.03 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Trunk)(n=213,263,46,55) | 0.45 units on a scale | Standard Deviation 0.77 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Trunk)(n=347,348,74,76) | 2.38 units on a scale | Standard Deviation 0.94 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Lower limbs)(n=305,327,69,72) | 0.90 units on a scale | Standard Deviation 1.05 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Upper limbs)(n=376,374,74,76) | 2.79 units on a scale | Standard Deviation 0.81 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Erythema(Head\Neck)(n=354,356,74,76) | 1.79 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Upper limbs)(n=347,348,74,76) | 2.29 units on a scale | Standard Deviation 0.98 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Lower limbs)(n=363,366,74,75) | 2.80 units on a scale | Standard Deviation 0.93 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Trunk)(n=376,374,74,76) | 2.61 units on a scale | Standard Deviation 0.95 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Head\Neck)(n=305,327,69,72) | 0.68 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Erythema(Head\Neck)(n=347,348,74,76) | 1.93 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Scaling(Lower limbs)(n=369,367,73,76) | 2.67 units on a scale | Standard Deviation 0.81 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Baseline:Scaling(Lower limbs)(n=376,374,74,76) | 3.03 units on a scale | Standard Deviation 0.8 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Lower limbs)(n=354,356,74,76) | 2.41 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Upper limbs)(n=213,263,46,55) | 0.85 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Head\Neck)(n=363,366,74,75) | 1.95 units on a scale | Standard Deviation 1.09 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Head\Neck)(n=369,367,73,76) | 2.07 units on a scale | Standard Deviation 0.93 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Trunk)(n=354,356,74,76) | 2.14 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Upper limbs)(n=354,356,74,76) | 2.20 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Induration(Trunk)(n=194,239,38,42) | 0.50 units on a scale | Standard Deviation 0.77 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Upper limbs)(n=369,367,73,76) | 2.57 units on a scale | Standard Deviation 0.87 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Lower limbs)(n=363,366,74,75) | 2.51 units on a scale | Standard Deviation 0.84 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Scaling(Head\Neck)(n=354,356,74,76) | 1.79 units on a scale | Standard Deviation 1.1 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Head\Neck)(n=363,366,74,75) | 2.05 units on a scale | Standard Deviation 0.97 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Trunk)(n=369,367,73,76) | 2.55 units on a scale | Standard Deviation 0.9 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Head\Neck)(n=194,239,38,42) | 0.48 units on a scale | Standard Deviation 0.77 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Trunk)(n=327,338,74,76) | 1.59 units on a scale | Standard Deviation 0.98 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Upper limbs)(n=305,327,69,72) | 1.10 units on a scale | Standard Deviation 1.02 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Lower limbs)(n=327,338,74,76) | 1.78 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Upper limbs)(n=327,338,74,76) | 1.55 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Erythema(Head\Neck)(n=327,338,74,76) | 1.11 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Lower limbs)(n=354,356,74,76) | 2.51 units on a scale | Standard Deviation 0.82 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Head\Neck)(n=327,338,74,76) | 0.89 units on a scale | Standard Deviation 0.93 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Lower limbs)(n=340,345,74,76) | 2.34 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Lower limbs)(n=213,263,46,55) | 0.71 units on a scale | Standard Deviation 0.9 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Lower limbs)(n=363,366,74,75) | 2.45 units on a scale | Standard Deviation 0.9 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Upper limbs)(n=327,338,74,76) | 1.37 units on a scale | Standard Deviation 0.86 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Erythema(Lower limbs)(n=369,367,73,76) | 2.91 units on a scale | Standard Deviation 0.85 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Trunk)(n=340,345,74,76) | 1.95 units on a scale | Standard Deviation 1.08 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Trunk)(n=213,263,46,55) | 0.45 units on a scale | Standard Deviation 0.74 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Trunk)(n=327,338,74,76) | 1.26 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Upper limbs)(n=194,239,38,42) | 0.88 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Upper limbs)(n=340,345,74,76) | 2.11 units on a scale | Standard Deviation 0.86 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Induration(Head\Neck)(n=213,263,46,55) | 0.38 units on a scale | Standard Deviation 0.73 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Induration(Lower limbs)(n=327,338,74,76) | 1.46 units on a scale | Standard Deviation 0.94 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Upper limbs)(n=363,366,74,75) | 2.40 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Scaling(Head\Neck)(n=340,345,74,76) | 1.68 units on a scale | Standard Deviation 1.16 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Head\Neck)(n=369,367,73,76) | 1.86 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Head\Neck)(n=327,338,74,76) | 1.03 units on a scale | Standard Deviation 1.06 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Head\Neck)(n=194,239,38,42) | 0.43 units on a scale | Standard Deviation 0.77 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Lower limbs)(n=340,345,74,76) | 2.33 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Trunk)(n=354,356,74,76) | 2.26 units on a scale | Standard Deviation 0.91 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Upper limbs)(n=327,338,74,76) | 1.37 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Upper limbs)(n=354,356,74,76) | 2.33 units on a scale | Standard Deviation 0.87 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Trunk)(n=213,263,46,55) | 0.47 units on a scale | Standard Deviation 0.84 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Erythema(Upper limbs)(n=363,366,74,75) | 2.53 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Trunk)(n=327,338,74,76) | 1.21 units on a scale | Standard Deviation 1.02 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Trunk)(n=194,239,38,42) | 0.48 units on a scale | Standard Deviation 0.71 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Trunk)(n=340,345,74,76) | 2.11 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Upper limbs)(n=369,367,73,76) | 2.53 units on a scale | Standard Deviation 0.84 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 20:Scaling(Lower limbs)(n=327,338,74,76) | 1.50 units on a scale | Standard Deviation 1.09 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Upper limbs)(n=194,239,38,42) | 0.81 units on a scale | Standard Deviation 0.97 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Upper limbs)(n=340,345,74,76) | 2.16 units on a scale | Standard Deviation 0.9 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Induration(Head\Neck)(n=363,366,74,75) | 1.72 units on a scale | Standard Deviation 0.99 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Head\Neck)(n=305,327,69,72) | 0.76 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Induration(Head\Neck)(n=340,345,74,76) | 1.53 units on a scale | Standard Deviation 1 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Lower limbs)(n=340,345,74,76) | 2.46 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 8:Induration(Head\Neck)(n=354,356,74,76) | 1.64 units on a scale | Standard Deviation 1.07 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Upper limbs)(n=305,327,69,72) | 1.15 units on a scale | Standard Deviation 0.96 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 4:Scaling(Trunk)(n=363,366,74,75) | 2.17 units on a scale | Standard Deviation 0.79 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Scaling(Upper limbs)(n=213,263,46,55) | 0.89 units on a scale | Standard Deviation 1.03 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Trunk)(n=369,367,73,76) | 2.38 units on a scale | Standard Deviation 0.92 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Trunk)(n=305,327,69,72) | 0.88 units on a scale | Standard Deviation 1.05 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Erythema(Lower limbs)(n=194,239,38,42) | 0.79 units on a scale | Standard Deviation 1.05 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Trunk)(n=340,345,74,76) | 2.30 units on a scale | Standard Deviation 1.03 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Scaling(Trunk)(n=305,327,69,72) | 0.79 units on a scale | Standard Deviation 1.01 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Erythema(Lower limbs)(n=305,327,69,72) | 0.99 units on a scale | Standard Deviation 1.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 52:Scaling(Trunk)(n=194,239,38,42) | 0.45 units on a scale | Standard Deviation 0.74 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Upper limbs)(n=340,345,74,76) | 2.28 units on a scale | Standard Deviation 0.89 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 40:Erythema(Upper limbs)(n=213,263,46,55) | 0.78 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Head\Neck)(n=305,327,69,72) | 0.60 units on a scale | Standard Deviation 0.88 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 16:Erythema(Head\Neck)(n=340,345,74,76) | 1.75 units on a scale | Standard Deviation 1.05 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 12:Scaling(Lower limbs)(n=347,348,74,76) | 2.30 units on a scale | Standard Deviation 0.99 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 2:Induration(Lower limbs)(n=369,367,73,76) | 2.66 units on a scale | Standard Deviation 0.79 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Component Scores | Week 28:Induration(Upper limbs)(n=305,327,69,72) | 0.94 units on a scale | Standard Deviation 0.99 |
Secondary
Psoriasis Area and Severity Index (PASI) Score
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Baseline, Week 2, 4, 8,12,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Baseline (n=376,374,74,76) | 22.96 units on a scale | Standard Deviation 8.8 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 2 (n=369,367,73,76) | 18.62 units on a scale | Standard Deviation 8.47 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 4 (n=363,366,74,76) | 14.84 units on a scale | Standard Deviation 8.27 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 8 (n=354,356,74,76) | 10.98 units on a scale | Standard Deviation 8.39 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 12 (n=347,348,74,76) | 9.22 units on a scale | Standard Deviation 8.58 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 16 (n=340,345,74,76) | 8.16 units on a scale | Standard Deviation 8.77 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 20 (n=327,338,74,76) | 6.76 units on a scale | Standard Deviation 7.71 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 28 (n=305,327,69,72) | 5.62 units on a scale | Standard Deviation 6.56 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 40 (n=213,263,46,55) | 3.33 units on a scale | Standard Deviation 4.65 |
| CP-690,550 5mg | Psoriasis Area and Severity Index (PASI) Score | Week 52 (n=194,239,38,42) | 3.24 units on a scale | Standard Deviation 4.16 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 4 (n=363,366,74,76) | 12.60 units on a scale | Standard Deviation 8.44 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 40 (n=213,263,46,55) | 2.74 units on a scale | Standard Deviation 4.66 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 8 (n=354,356,74,76) | 8.23 units on a scale | Standard Deviation 7.65 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 12 (n=347,348,74,76) | 6.39 units on a scale | Standard Deviation 7.22 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 16 (n=340,345,74,76) | 5.36 units on a scale | Standard Deviation 6.71 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 20 (n=327,338,74,76) | 4.46 units on a scale | Standard Deviation 5.83 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 52 (n=194,239,38,42) | 2.60 units on a scale | Standard Deviation 3.89 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 28 (n=305,327,69,72) | 4.15 units on a scale | Standard Deviation 6.13 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Baseline (n=376,374,74,76) | 21.88 units on a scale | Standard Deviation 8.41 |
| CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 2 (n=369,367,73,76) | 17.19 units on a scale | Standard Deviation 8.94 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 28 (n=305,327,69,72) | 6.71 units on a scale | Standard Deviation 7.41 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 20 (n=327,338,74,76) | 10.62 units on a scale | Standard Deviation 8.71 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 52 (n=194,239,38,42) | 3.49 units on a scale | Standard Deviation 4.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Baseline (n=376,374,74,76) | 22.58 units on a scale | Standard Deviation 8.62 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 8 (n=354,356,74,76) | 17.42 units on a scale | Standard Deviation 9.42 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 16 (n=340,345,74,76) | 16.59 units on a scale | Standard Deviation 10.83 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 40 (n=213,263,46,55) | 4.21 units on a scale | Standard Deviation 6.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 2 (n=369,367,73,76) | 21.46 units on a scale | Standard Deviation 8.88 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 12 (n=347,348,74,76) | 17.07 units on a scale | Standard Deviation 10.27 |
| Placebo | Psoriasis Area and Severity Index (PASI) Score | Week 4 (n=363,366,74,76) | 19.43 units on a scale | Standard Deviation 9.35 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 12 (n=347,348,74,76) | 17.29 units on a scale | Standard Deviation 8.44 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 28 (n=305,327,69,72) | 5.38 units on a scale | Standard Deviation 8.35 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 16 (n=340,345,74,76) | 16.59 units on a scale | Standard Deviation 8.67 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 52 (n=194,239,38,42) | 2.88 units on a scale | Standard Deviation 3.56 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 20 (n=327,338,74,76) | 9.28 units on a scale | Standard Deviation 8.2 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 2 (n=369,367,73,76) | 19.53 units on a scale | Standard Deviation 7.72 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 4 (n=363,366,74,76) | 18.87 units on a scale | Standard Deviation 7.86 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 8 (n=354,356,74,76) | 18.16 units on a scale | Standard Deviation 9.04 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Baseline (n=376,374,74,76) | 22.36 units on a scale | Standard Deviation 8.43 |
| Placebo, Then CP-690,550 10 mg | Psoriasis Area and Severity Index (PASI) Score | Week 40 (n=213,263,46,55) | 2.90 units on a scale | Standard Deviation 3.92 |
Secondary
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Percentage of participants reporting healthcare resource use events and employment status, work impacted events due to psoriasis, and absence or sick leave for work due to psoriasis at Week 16 are reported. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.
Time frame: Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. 'n' signifies participants who were evaluable (answered respective question for this measure) for specified parameter for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Healthcare Resource use events(n=34,42,12) | 100.00 percentage of participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Employment(n=315,315,146) | 66.67 percentage of participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Work Impacted events due to Psoriasis(n=105,80,39) | 20.00 percentage of participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Absence/Sick leave due to Psoriasis(n=211,234,109) | 21.33 percentage of participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Absence/Sick leave due to Psoriasis(n=211,234,109) | 22.65 percentage of participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Healthcare Resource use events(n=34,42,12) | 100.00 percentage of participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Work Impacted events due to Psoriasis(n=105,80,39) | 12.50 percentage of participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Employment(n=315,315,146) | 74.60 percentage of participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Absence/Sick leave due to Psoriasis(n=211,234,109) | 22.94 percentage of participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Employment(n=315,315,146) | 74.66 percentage of participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Work Impacted events due to Psoriasis(n=105,80,39) | 20.51 percentage of participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Healthcare Resource Use Events and Employment Status | Healthcare Resource use events(n=34,42,12) | 100.00 percentage of participants |
Secondary
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Participants (currently employed \[Emp\]) answered (Yes/No \[Y/N\]): Were you absent or on sick leave from work due to psoriasis today?, and participants (unemployed \[UEmp\]) answered (Yes/No): Are you unemployed due to your psoriasis? Baseline is the latest pre-dose measurement. Week 16 includes all reported log up to Week 16 (excluding Baseline). Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.
Time frame: Baseline, Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:Emp,Absent/Sick Leave:Y(n=218,234,122) | 50 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:Emp,Absent/Sick Leave:N(n=218,234,122) | 168 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:UEmp,due to Psoriasis:Y(n=120,97,52) | 28 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:UEmp,due to Psoriasis:N(n=120,97,52) | 92 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:Emp,Absent/Sick Leave:Y(n=210,234,109) | 45 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:Emp,Absent/Sick Leave:N(n=210,234,109) | 165 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:UEmp,due to Psoriasis:Y(n=105,80,38) | 21 participants |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:UEmp,due to Psoriasis:N(n=105,80,38) | 84 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:UEmp,due to Psoriasis:Y(n=120,97,52) | 16 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:UEmp,due to Psoriasis:Y(n=105,80,38) | 10 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:UEmp,due to Psoriasis:N(n=120,97,52) | 81 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:Emp,Absent/Sick Leave:Y(n=210,234,109) | 53 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:Emp,Absent/Sick Leave:N(n=210,234,109) | 181 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:Emp,Absent/Sick Leave:Y(n=218,234,122) | 59 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:Emp,Absent/Sick Leave:N(n=218,234,122) | 175 participants |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:UEmp,due to Psoriasis:N(n=105,80,38) | 70 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:UEmp,due to Psoriasis:Y(n=120,97,52) | 10 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:Emp,Absent/Sick Leave:N(n=218,234,122) | 95 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:Emp,Absent/Sick Leave:Y(n=218,234,122) | 27 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Baseline:UEmp,due to Psoriasis:N(n=120,97,52) | 42 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:UEmp,due to Psoriasis:Y(n=105,80,38) | 8 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:Emp,Absent/Sick Leave:N(n=210,234,109) | 84 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:Emp,Absent/Sick Leave:Y(n=210,234,109) | 25 participants |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Impact of Psoriasis on Work | Week 16:UEmp,due to Psoriasis:N(n=105,80,38) | 30 participants |
Secondary
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners, Dermatologist and Rheumatologist. Baseline is the latest pre-dose measurement. Week 16 includes all reported log data to Week 16 (excluding Baseline). Participants may have response in more than 1 category. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.
Time frame: Baseline, Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from a site were excluded due to GCP compliance issues. 'n' signifies participants evaluable at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16: Surgeon(n=67,68,30) | 5 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Surgeon(n=45,45,24) | 0 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Gastroenterologist(n=45,45,24) | 0 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Rheumatologist(n=45,45,24) | 0 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Nurse(n=45,45,24) | 15 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Psychiatrist(n=45,45,24) | 1 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Nurse(n=67,68,30) | 14 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Other(n=45,45,24) | 0 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Psychiatrist(n=67,68,30) | 1 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:General Practitioner(n=45,45,24) | 4 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:General Practitioner(n=67,68,30) | 31 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Others(n=67,68,30) | 18 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Cardiologist(n=45,45,24) | 0 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Dermatologist(n=67,68,30) | 25 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Gastroenterologist(n=67,68,30) | 1 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Cardiologist(n=67,68,30) | 5 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Rheumatologist(n=67,68,30) | 3 events |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Dermatologist(n=45,45,24) | 44 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Rheumatologist(n=67,68,30) | 1 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Cardiologist(n=67,68,30) | 0 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Gastroenterologist(n=67,68,30) | 1 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Gastroenterologist(n=45,45,24) | 1 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Psychiatrist(n=67,68,30) | 0 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Dermatologist(n=45,45,24) | 44 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16: Surgeon(n=67,68,30) | 2 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Nurse(n=67,68,30) | 11 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Others(n=67,68,30) | 14 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Psychiatrist(n=45,45,24) | 0 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:General Practitioner(n=45,45,24) | 5 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Surgeon(n=45,45,24) | 0 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Nurse(n=45,45,24) | 16 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Rheumatologist(n=45,45,24) | 0 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Other(n=45,45,24) | 0 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:General Practitioner(n=67,68,30) | 34 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Dermatologist(n=67,68,30) | 25 events |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Cardiologist(n=45,45,24) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Dermatologist(n=67,68,30) | 9 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:General Practitioner(n=45,45,24) | 2 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Dermatologist(n=45,45,24) | 22 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Rheumatologist(n=45,45,24) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Cardiologist(n=45,45,24) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Gastroenterologist(n=45,45,24) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Psychiatrist(n=45,45,24) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Surgeon(n=45,45,24) | 1 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Nurse(n=45,45,24) | 8 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Baseline:Other(n=45,45,24) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:General Practitioner(n=67,68,30) | 17 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Nurse(n=67,68,30) | 5 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Rheumatologist(n=67,68,30) | 2 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Cardiologist(n=67,68,30) | 1 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Gastroenterologist(n=67,68,30) | 1 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Psychiatrist(n=67,68,30) | 0 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16: Surgeon(n=67,68,30) | 2 events |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Interaction With Healthcare Professional | Week 16:Others(n=67,68,30) | 16 events |
Secondary
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Percent absent hours = (hours absent from work/hours scheduled to work) multiplied by 100. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.
Time frame: Baseline, Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. 'n' signifies participants evaluable for specified timepoint for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Baseline (n=48, 58, 27) | 64.89 percentage of scheduled hours | Standard Deviation 34.42 |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Week 16 (n=45, 53, 25) | 68.39 percentage of scheduled hours | Standard Deviation 32.19 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Baseline (n=48, 58, 27) | 70.32 percentage of scheduled hours | Standard Deviation 35.39 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Week 16 (n=45, 53, 25) | 72.88 percentage of scheduled hours | Standard Deviation 29.69 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Baseline (n=48, 58, 27) | 73.36 percentage of scheduled hours | Standard Deviation 34.09 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Percent Absent Hours | Week 16 (n=45, 53, 25) | 73.82 percentage of scheduled hours | Standard Deviation 34.05 |
Secondary
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants rate how much psoriasis affected their ability to work by reporting a number from 0 to 10, where 0 means ability to work was not affected by psoriasis, and 10 means ability to work was completely affected by psoriasis. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint.
Time frame: Baseline, Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies participants evaluable at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Baseline (n=223, 232, 124) | 2.50 units on a scale | Standard Deviation 3.06 |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Week 16 (n=210, 234, 109) | 1.15 units on a scale | Standard Deviation 2.18 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Baseline (n=223, 232, 124) | 2.61 units on a scale | Standard Deviation 2.99 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Week 16 (n=210, 234, 109) | 0.85 units on a scale | Standard Deviation 1.94 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Baseline (n=223, 232, 124) | 2.32 units on a scale | Standard Deviation 2.99 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Psoriasis Affecting Ability to Work | Week 16 (n=210, 234, 109) | 2.07 units on a scale | Standard Deviation 3.21 |
Secondary
Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use, and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work. Baseline is the latest pre-dose measurement. Participants reported hours scheduled to work and hours absent from work. Data was not analyzed beyond Week 16 as per study team's decision because Week 0 - 16 period was considered sufficient to provide clear reflection of Ps-HCRU endpoint. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.
Time frame: Baseline, Week 16
Population: FAS included participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure for specified parameter for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline:Hour Scheduled to work(n=50,59,27) | 8.84 hours | Standard Deviation 3.02 |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline:Hour Absent from work(n=49,58,27) | 5.86 hours | Standard Deviation 4.24 |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Week 16:Hours Scheduled to work(n=45,53,25) | 8.82 hours | Standard Deviation 2.2 |
| CP-690,550 5mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Week 16:Hours Absent from work(n=45,53,25) | 5.93 hours | Standard Deviation 3.26 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Week 16:Hours Absent from work(n=45,53,25) | 6.21 hours | Standard Deviation 3.15 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline:Hour Scheduled to work(n=50,59,27) | 8.56 hours | Standard Deviation 2.74 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Week 16:Hours Scheduled to work(n=45,53,25) | 8.40 hours | Standard Deviation 1.75 |
| CP-690,550 10 mg | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline:Hour Absent from work(n=49,58,27) | 5.74 hours | Standard Deviation 3.01 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Week 16:Hours Absent from work(n=45,53,25) | 5.96 hours | Standard Deviation 3.13 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline:Hour Absent from work(n=49,58,27) | 5.74 hours | Standard Deviation 2.78 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Week 16:Hours Scheduled to work(n=45,53,25) | 8.04 hours | Standard Deviation 1.72 |
| Placebo | Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU) - Work Hours and Absent Hours | Baseline:Hour Scheduled to work(n=50,59,27) | 8.07 hours | Standard Deviation 1.71 |
Secondary
Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear'
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Baseline up to Week 16
Population: FAS participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CP-690,550 5mg | Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | 12.0 weeks |
| CP-690,550 10 mg | Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | 8.0 weeks |
| Placebo | Time to Achieve a Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' | NA weeks |
p-value: <0.0001Log Rank
p-value: <0.0001Log Rank
p-value: <0.0001Log Rank
Secondary
Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Baseline up to Week 16
Population: FAS participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'N' signifies those participants who were evaluable for this measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CP-690,550 5mg | Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response | 8.0 weeks |
| CP-690,550 10 mg | Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response | 8.0 weeks |
| Placebo | Time to Achieve Psoriasis Area and Severity Index 50 (PASI 50) Response | NA weeks |
p-value: <0.0001Log Rank
p-value: <0.0001Log Rank
p-value: <0.0001Log Rank
Secondary
Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response
The PASI quantifies the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.
Time frame: Baseline up to Week 16
Population: FAS participants who were randomized to study and received at least 1 dose investigational drug (CP-690,550 or placebo). Participants from 1 site were excluded due to GCP compliance issues. Here 'N' signifies those participants who were evaluable for this measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CP-690,550 5mg | Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response | 16.0 weeks |
| CP-690,550 10 mg | Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response | 12.0 weeks |
| Placebo | Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response | NA weeks |
p-value: <0.0001Log Rank
p-value: <0.0001Log Rank
p-value: <0.0001Log Rank
Secondary
Total Body Surface Area (BSA) With Psoriasis
Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.
Time frame: Baseline, Week 2, 4, 8,16, 20, 28, 40, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Baseline (n=376,374,74,76) | 30.94 percentage of BSA | Standard Deviation 17.97 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 2 (n=369,367,73,76) | 28.25 percentage of BSA | Standard Deviation 17.19 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 4 (n=363,366,74,75) | 25.09 percentage of BSA | Standard Deviation 17.39 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 8 (n=354,356,74,76) | 19.03 percentage of BSA | Standard Deviation 15.59 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 12 (n=354,356,74,76) | 15.54 percentage of BSA | Standard Deviation 15.88 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 16 (n=340,345,74,76) | 13.40 percentage of BSA | Standard Deviation 16.3 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 20 (n=327,338,74,76) | 11.56 percentage of BSA | Standard Deviation 15.6 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 28 (n=305,327,69,72) | 9.24 percentage of BSA | Standard Deviation 13.29 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 40 (n=213,263,46,55) | 5.24 percentage of BSA | Standard Deviation 9.66 |
| CP-690,550 5mg | Total Body Surface Area (BSA) With Psoriasis | Week 52 (n=194,239,38,42) | 4.37 percentage of BSA | Standard Deviation 7.69 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 4 (n=363,366,74,75) | 21.98 percentage of BSA | Standard Deviation 16.48 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 40 (n=213,263,46,55) | 3.66 percentage of BSA | Standard Deviation 7.68 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 8 (n=354,356,74,76) | 15.63 percentage of BSA | Standard Deviation 15.38 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 12 (n=354,356,74,76) | 11.46 percentage of BSA | Standard Deviation 14.23 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 16 (n=340,345,74,76) | 9.11 percentage of BSA | Standard Deviation 12.62 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 20 (n=327,338,74,76) | 7.16 percentage of BSA | Standard Deviation 11.11 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 52 (n=194,239,38,42) | 3.32 percentage of BSA | Standard Deviation 7.23 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 28 (n=305,327,69,72) | 6.04 percentage of BSA | Standard Deviation 10.7 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Baseline (n=376,374,74,76) | 28.49 percentage of BSA | Standard Deviation 16.27 |
| CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 2 (n=369,367,73,76) | 26.40 percentage of BSA | Standard Deviation 16.27 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 28 (n=305,327,69,72) | 11.23 percentage of BSA | Standard Deviation 13.23 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 20 (n=327,338,74,76) | 18.71 percentage of BSA | Standard Deviation 16.89 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 52 (n=194,239,38,42) | 4.91 percentage of BSA | Standard Deviation 7.48 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Baseline (n=376,374,74,76) | 30.10 percentage of BSA | Standard Deviation 17.97 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 8 (n=354,356,74,76) | 26.95 percentage of BSA | Standard Deviation 17.78 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 16 (n=340,345,74,76) | 24.95 percentage of BSA | Standard Deviation 19.27 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 40 (n=213,263,46,55) | 6.91 percentage of BSA | Standard Deviation 13.56 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 2 (n=369,367,73,76) | 30.63 percentage of BSA | Standard Deviation 18.36 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 12 (n=354,356,74,76) | 25.67 percentage of BSA | Standard Deviation 18.51 |
| Placebo | Total Body Surface Area (BSA) With Psoriasis | Week 4 (n=363,366,74,75) | 29.46 percentage of BSA | Standard Deviation 18.5 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 12 (n=354,356,74,76) | 26.80 percentage of BSA | Standard Deviation 17.99 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 28 (n=305,327,69,72) | 9.53 percentage of BSA | Standard Deviation 15.33 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 16 (n=340,345,74,76) | 26.04 percentage of BSA | Standard Deviation 17.73 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 52 (n=194,239,38,42) | 3.32 percentage of BSA | Standard Deviation 5.62 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 20 (n=327,338,74,76) | 17.65 percentage of BSA | Standard Deviation 16.84 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 2 (n=369,367,73,76) | 29.59 percentage of BSA | Standard Deviation 17.47 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 4 (n=363,366,74,75) | 29.48 percentage of BSA | Standard Deviation 17.49 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 8 (n=354,356,74,76) | 28.07 percentage of BSA | Standard Deviation 18.12 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Baseline (n=376,374,74,76) | 30.27 percentage of BSA | Standard Deviation 17.98 |
| Placebo, Then CP-690,550 10 mg | Total Body Surface Area (BSA) With Psoriasis | Week 40 (n=213,263,46,55) | 4.52 percentage of BSA | Standard Deviation 8.56 |
Secondary
Work Limitation Questionnaire (WLQ) Index Score
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: Time Management scale (5-items); Physical Demands scale (6-item); Mental-Interpersonal Demands Scale (9-items); Output Demands Scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). The WLQ Index score is the weighted sum of the scores from the 4 WLQ scales (total score: 0 \[no loss\] to 100 \[complete loss of work\]).
Time frame: Baseline, Week 8, 16, 28, 52
Population: FAS. Analysis population for Placebo, CP-690,550 groups included FAS participants who were re-randomized at Week 16 to receive CP-690,550 5 mg or 10 mg. Participants from 1 site were excluded due to GCP compliance issues. Here 'n' signifies those participants who were evaluable for this measure at specified time point for each arm, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 5mg | Work Limitation Questionnaire (WLQ) Index Score | Week 28 (n=249,277,56,61) | 5.93 units on a scale | Standard Deviation 6.03 |
| CP-690,550 5mg | Work Limitation Questionnaire (WLQ) Index Score | Week 8 (n=293,302,63,61) | 6.89 units on a scale | Standard Deviation 6.79 |
| CP-690,550 5mg | Work Limitation Questionnaire (WLQ) Index Score | Week 52 (n=164,205,31,38) | 5.86 units on a scale | Standard Deviation 6.35 |
| CP-690,550 5mg | Work Limitation Questionnaire (WLQ) Index Score | Week 16 (n=278,292,64,61) | 6.28 units on a scale | Standard Deviation 6.31 |
| CP-690,550 5mg | Work Limitation Questionnaire (WLQ) Index Score | Baseline (n=324,318,66,68) | 7.77 units on a scale | Standard Deviation 5.94 |
| CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 16 (n=278,292,64,61) | 6.44 units on a scale | Standard Deviation 6.48 |
| CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 28 (n=249,277,56,61) | 5.71 units on a scale | Standard Deviation 5.64 |
| CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 52 (n=164,205,31,38) | 5.79 units on a scale | Standard Deviation 6.03 |
| CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 8 (n=293,302,63,61) | 6.99 units on a scale | Standard Deviation 6.68 |
| CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Baseline (n=324,318,66,68) | 8.26 units on a scale | Standard Deviation 6.59 |
| Placebo | Work Limitation Questionnaire (WLQ) Index Score | Week 16 (n=278,292,64,61) | 7.27 units on a scale | Standard Deviation 6.97 |
| Placebo | Work Limitation Questionnaire (WLQ) Index Score | Baseline (n=324,318,66,68) | 7.63 units on a scale | Standard Deviation 5.65 |
| Placebo | Work Limitation Questionnaire (WLQ) Index Score | Week 8 (n=293,302,63,61) | 7.04 units on a scale | Standard Deviation 6.41 |
| Placebo | Work Limitation Questionnaire (WLQ) Index Score | Week 28 (n=249,277,56,61) | 6.11 units on a scale | Standard Deviation 6.76 |
| Placebo | Work Limitation Questionnaire (WLQ) Index Score | Week 52 (n=164,205,31,38) | 6.48 units on a scale | Standard Deviation 6.41 |
| Placebo, Then CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 28 (n=249,277,56,61) | 7.45 units on a scale | Standard Deviation 7.27 |
| Placebo, Then CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 8 (n=293,302,63,61) | 8.53 units on a scale | Standard Deviation 7.11 |
| Placebo, Then CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Baseline (n=324,318,66,68) | 7.78 units on a scale | Standard Deviation 6.32 |
| Placebo, Then CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 16 (n=278,292,64,61) | 7.14 units on a scale | Standard Deviation 6.46 |
| Placebo, Then CP-690,550 10 mg | Work Limitation Questionnaire (WLQ) Index Score | Week 52 (n=164,205,31,38) | 5.23 units on a scale | Standard Deviation 5.97 |